<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Clobazam add‐on therapy for drug‐resistant epilepsy - Bresnahan, R - 2019 | Cochrane Library</title> <meta content="Clobazam add‐on therapy for drug‐resistant epilepsy - Bresnahan, R - 2019 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004154.pub5/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Clobazam add‐on therapy for drug‐resistant epilepsy - Bresnahan, R - 2019 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004154.pub5/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD004154.pub5" name="dc.identifier" scheme="DOI"/> <meta content="Clobazam add‐on therapy for drug‐resistant epilepsy" name="citation_title"/> <meta content="Rebecca Bresnahan" name="citation_author"/> <meta content="Institute of Translational Medicine, University of Liverpool" name="citation_author_institution"/> <meta content="rebecca.bresnahan@liverpool.ac.uk" name="citation_author_email"/> <meta content="Kirsty J Martin‐McGill" name="citation_author"/> <meta content="John Williamson" name="citation_author"/> <meta content="The Walton Centre NHS Foundation Trust" name="citation_author_institution"/> <meta content="Benedict D Michael" name="citation_author"/> <meta content="University of Liverpool" name="citation_author_institution"/> <meta content="Anthony G Marson" name="citation_author"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="10" name="citation_issue"/> <meta content="10.1002/14651858.CD004154.pub5" name="citation_doi"/> <meta content="2019" name="citation_date"/> <meta content="2019/10/22" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004154.pub5/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004154.pub5/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004154.pub5/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Anticonvulsants [administration &amp; dosage, *therapeutic use]; Benzodiazepines [administration &amp; dosage, *therapeutic use]; Clobazam; Epilepsy [*drug therapy]; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004154.pub5&amp;doi=10.1002/14651858.CD004154.pub5&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004154.pub5&amp;doi=10.1002/14651858.CD004154.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004154.pub5&amp;doi=10.1002/14651858.CD004154.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004154.pub5&amp;doi=10.1002/14651858.CD004154.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004154.pub5&amp;doi=10.1002/14651858.CD004154.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004154.pub5&amp;doi=10.1002/14651858.CD004154.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004154.pub5&amp;doi=10.1002/14651858.CD004154.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004154.pub5&amp;doi=10.1002/14651858.CD004154.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004154.pub5&amp;doi=10.1002/14651858.CD004154.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004154.pub5&amp;doi=10.1002/14651858.CD004154.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004154.pub5&amp;doi=10.1002/14651858.CD004154.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004154.pub5&amp;doi=10.1002/14651858.CD004154.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004154.pub5&amp;doi=10.1002/14651858.CD004154.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004154.pub5&amp;doi=10.1002/14651858.CD004154.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004154.pub5&amp;doi=10.1002/14651858.CD004154.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004154.pub5&amp;doi=10.1002/14651858.CD004154.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004154.pub5&amp;doi=10.1002/14651858.CD004154.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004154.pub5&amp;doi=10.1002/14651858.CD004154.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004154.pub5&amp;doi=10.1002/14651858.CD004154.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004154.pub5&amp;doi=10.1002/14651858.CD004154.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004154.pub5&amp;doi=10.1002/14651858.CD004154.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004154.pub5&amp;doi=10.1002/14651858.CD004154.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004154.pub5&amp;doi=10.1002/14651858.CD004154.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="bzu3XIhG";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD004154\x2epub5\x26doi\x3d10\x2e1002\x2f14651858\x2eCD004154\x2epub5\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004154\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004154\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANT","fa","fr","zh_HANS","ms"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD004154.pub5",title:"Clobazam add\\u2010on therapy for drug\\u2010resistant epilepsy",firstPublishedDate:"Oct 22, 2019 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Epilepsy Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=bzu3XIhG&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004154.pub5&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD004154.pub5';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD004154.pub5/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD004154.pub5/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004154.pub5%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD004154.pub5/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD004154.pub5/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD004154.pub5/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD004154.pub5/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD004154.PUB5" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD004154.pub5/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD004154.PUB5" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD004154.pub5/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD004154.pub5/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>2783 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD004154.pub5" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004154.pub5/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004154.pub5/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004154.pub5/full#CD004154-abs-0005"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004154.pub5/full#CD004154-sec-0101"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004154.pub5/full#CD004154-sec-0029"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004154.pub5/full#CD004154-sec-0030"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004154.pub5/full#CD004154-sec-0035"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004154.pub5/full#CD004154-sec-0036"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004154.pub5/full#CD004154-sec-0075"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004154.pub5/full#CD004154-sec-0095"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD004154.pub5/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004154.pub5/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004154.pub5/appendices#CD004154-sec-0105"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004154.pub5/references#characteristicStudies"> Characteristics of studies </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004154.pub5/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004154.pub5/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004154.pub5/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD004154.pub5/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD004154.pub5/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD004154.pub5/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2019 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD004154.pub5/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Clobazam add‐on therapy for drug‐resistant epilepsy</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004154.pub5/information#CD004154-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Rebecca Bresnahan</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004154.pub5/information#CD004154-cr-0003">Kirsty J Martin‐McGill</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004154.pub5/information#CD004154-cr-0004">John Williamson</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004154.pub5/information#CD004154-cr-0005">Benedict D Michael</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004154.pub5/information#CD004154-cr-0006">Anthony G Marson</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD004154.pub5/information/en#CD004154-sec-0114">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 22 October 2019 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD004154.pub5/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD004154.pub5">https://doi.org/10.1002/14651858.CD004154.pub5</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD004154-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD004154-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD004154-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD004154-abs-0002">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD004154-abs-0003">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD004154-abs-0010">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD004154-abs-0001" lang="en"> <section id="CD004154-sec-0001"> <h3 class="title" id="CD004154-sec-0001">Background</h3> <p>Epilepsy affects approximately 1% of the population, with up to 30% of patients continuing to have seizures, despite antiepileptic drug treatment. Clobazam is a 1,5‐benzodiazepine and is commonly used as an add‐on treatment for drug‐resistant epilepsy. This review is an updated version of the original Cochrane Review, first published in 2008, and examines the most current literature regarding clobazam as an add‐on for drug‐resistant epilepsy. </p> </section> <section id="CD004154-sec-0002"> <h3 class="title" id="CD004154-sec-0002">Objectives</h3> <p>To assess the efficacy, effectiveness and tolerability of clobazam as an add‐on therapy for drug‐resistant generalised‐onset and focal‐onset seizures, with or without secondary generalisation, in adults and children. </p> </section> <section id="CD004154-sec-0003"> <h3 class="title" id="CD004154-sec-0003">Search methods</h3> <p>For the latest update, we searched the following databases on 9 October 2018: Cochrane Register of Studies (CRS Web), which includes the Cochrane Epilepsy Group Specialized Register and the Cochrane Central Register of Controlled Trials (CENTRAL), Medline (Ovid) 1946 to 8 October, 2018, <a href="https://clinicaltrials.gov/" target="_blank">ClinicalTrials.gov</a>, and the WHO International Clinical Trials Registry Platform (<a href="http://apps.who.int/trialsearch/" target="_blank">ICTRP</a>). For some previous updates we also searched SCOPUS, DARE, and BIOSIS Previews, but these are no longer needed. (SCOPUS was searched as a substitute for EMBASE, but randomised and quasi‐randomised controlled trials in EMBASE are now included in CENTRAL; DARE ceased operation at the end of March 2015; BIOSIS Previews yielded no relevant items that were not found in the other databases). </p> </section> <section id="CD004154-sec-0004"> <h3 class="title" id="CD004154-sec-0004">Selection criteria</h3> <p>Randomised trials of add‐on clobazam, with adequate methods of allocation concealment, recruiting patients with drug‐resistant focal or generalised‐onset seizures, with a minimum treatment period of eight weeks. </p> </section> <section id="CD004154-sec-0005"> <h3 class="title" id="CD004154-sec-0005">Data collection and analysis</h3> <p>Two review authors independently selected trials for inclusion and extracted relevant data. The following outcomes were assessed: 50% or greater reduction in seizures, seizure freedom, treatment withdrawal and adverse events. </p> </section> <section id="CD004154-sec-0006"> <h3 class="title" id="CD004154-sec-0006">Main results</h3> <p>Four double‐blind, placebo‐controlled, cross‐over studies, representing 197 participants, were included in the review. All four studies were assessed as having unclear risk of bias due to the unavailability of methodological details. The studies demonstrated significant methodological heterogeneity and differences in outcome measures were noted. Consequently, it was not possible to summarise the data in a meta‐analysis. Instead, findings were summarised in a narrative data synthesis, Only two of the studies reported 50% or greater seizure reduction. They respectively reported that 57.7% and 52.4% of participants receiving add‐on clobazam experienced a 50% or greater reduction in seizure frequency, although publication bias needs to be considered (2 RCTs, n = 47, very low‐quality evidence). Seizure freedom was reported by three of the included studies. Collectively, 27 out of 175 patients were seizure‐free during treatment with clobazam (3 RCTs, n = 175, very low‐quality evidence). Two studies specifically stated that seizure freedom was not observed in any of the participants receiving add‐on placebo. Treatment withdrawal was reported by all four studies. There was a slightly higher incidence of treatment withdrawal associated with receiving clobazam, although the overall incidence was still fairly low (4 RCTs, n = 197, very low‐quality evidence). Adverse events were only described in two of the studies, reportedly 36% and 85% of participants experienced one or more adverse events whilst receiving clobazam. The most commonly reported adverse event was drowsiness. </p> </section> <section id="CD004154-sec-0007"> <h3 class="title" id="CD004154-sec-0007">Authors' conclusions</h3> <p>Clobazam as an add‐on treatment may reduce seizure frequency and may be most effective in focal‐onset seizures. It is important to recognise that this finding has been derived from very low‐quality evidence and from studies judged to have an unclear risk of bias. It remains unclear which population demographic will best benefit from clobazam and over what time‐frame. A large‐scale, randomised controlled trial, conducted over a greater period of time, incorporating subgroups with differing seizure types, is required to effectively inform clinical practice. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD004154-abs-0005" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD004154-abs-0005">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD004154-abs-0009">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD004154-abs-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD004154-abs-0008">Français</a> </li> <li class="section-language"> <a class="" href="full/ms#CD004154-abs-0012">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD004154-abs-0011">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD004154-abs-0006">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD004154-abs-0005" lang="en"> <h3>Clobazam as an add‐on treatment in the management of drug‐resistant epilepsy</h3> <p><b>Background</b><br/> Epilepsy is a disorder of repeated seizures. Whilst many people will achieve freedom from seizures on one antiepileptic medication, some may require multiple medications to try to reduce the number of seizures that they have. These people are said to have drug‐resistant epilepsy. </p> <p><b>Aim of the review</b><br/> Clobazam is an antiepileptic medication. Here, we examine the evidence from medical studies to determine how effective clobazam is at reducing the number of seizures that people have when used as an add‐on treatment by people with drug‐resistant epilepsy. </p> <p><b>Results</b><br/> We found four studies which had assessed clobazam as an add‐on treatment for drug‐resistant epilepsy. They included a total of 197 people. Two studies reported that more than half of the people given clobazam reached a 50% of greater reduction in the number of their seizures. Three of the studies reported how many people were seizure‐free whilst taking clobazam. In total, approximately 15% of people were seizure‐free when taking clobazam, compared to 0% when they were given placebo (a fake, inactive drug which should have no effect of epilepsy). All four studies reported how many people withdrew from treatment during the studies. Slightly more people withdrew from the studies when receiving clobazam (17 out of 197 people) than when receiving placebo (12 out of 197 people), but the rate of people withdrawing was still low overall. Clobazam was associated with side effects, in particular drowsiness. </p> <p>All four studies were of short duration. They used different methods, e.g. different lengths of treatment, and were of poor quality. The results suggest that clobazam reduces seizure frequency for people with drug‐resistant focal epilepsy (epilepsy that originates from one area of the brain), but there were not enough data to determine whether clobazam is as effective for generalised epilepsy (epilepsy involving the whole brain). The very low quality of the evidence provided by the four included studies means that we are very uncertain about whether the findings are accurate and, therefore, they must be taken and applied with caution. </p> <p>The evidence is current to October 2018.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD004154-sec-0101" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD004154-sec-0101"></div> <h3 class="title" id="CD004154-sec-0102">Implications for practice</h3> <section id="CD004154-sec-0102"> <p>For patients with drug‐resistant epilepsy, clobazam when used as an add‐on treatment may potentially reduce seizure frequency but we are very uncertain about this conclusion. There are more data to support this for patients with focal‐onset seizures than for patients with generalised‐onset seizures. The quality of existing data is very low and it is not possible to define the size of treatment effect. The adverse events most commonly reported were drowsiness, dizziness, and vertigo, but current data do not adequately define the adverse‐event profile of clobazam. Of importance, we must stress that the very low quality of evidence means that we are very uncertain about whether the effects described here are accurate of the true effectiveness and tolerability of clobazam. </p> </section> <h3 class="title" id="CD004154-sec-0103">Implications for research</h3> <section id="CD004154-sec-0103"> <p>To better inform clinical practice, we require various large‐scale, multi‐centre, parallel‐group, randomised, controlled trials comparing clobazam with placebo, as well as other add‐on treatments, for patients with drug‐resistant epilepsy. Future trials should recruit a heterogeneous population with well‐defined seizure and epilepsy types to allow the identification of patient factors, such as age, pathology, seizure types, and baseline antiepileptic drugs (AEDs), associated with the greatest benefit or harm. Of interest, research is increasingly being undertaken into epilepsy genetics, with regard to the factors contributing to 'drug‐resistant' epilepsy and identifying for whom which particular AEDs will achieve greatest efficacy. Such investigations could potentially be included in future research into clobazam. Additionally, longer‐term studies are necessary to fully assess the incidence of tolerance amongst patients. </p> <p>Of particular note for clinical practice, because it has been off‐patent for over 20 years, clobazam is cheaper than the newer AEDs available for use as add‐on treatments for drug‐resistant epilepsy. None of the studies included in this review, however, assessed cost‐effectiveness, evaluation of which would need to be undertaken in any future research to inform clinical practice. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD004154-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD004154-sec-0029"></div> <div class="table" id="CD004154-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Clobazam compared to Placebo in the management of drug‐resistant epilepsy</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Clobazam compared to Placebo in the management of drug‐resistant epilepsy</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> children or adults with drug‐resistant epilepsy<br/> <b>Setting:</b> outpatients<br/> <b>Intervention:</b> clobazam<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with Clobazam</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>50% reduction in seizure frequency</b><br/> Follow up (range): 9 weeks to 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>In both studies, more than half of the patients experienced a 50% or greater reduction in seizure frequency when receiving clobazam. One study reported that a significantly larger proportion of patients received a 50% or greater reduction whilst receiving clobazam, compared to placebo, whilst the other specifically reported that no patients receiving placebo experienced this outcome. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>47</b><br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>VERY LOW</b><sup>1, 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clobazam may increase the likelihood of a 50% or greater reduction in seizure frequency but we are very uncertain. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Seizure Freedom</b><br/> Follow up (range): 8 weeks to 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>3 studies reported that multiple patients (27/175, collectively) achieved seizure freedom when receiving clobazam. Two studies specifically stated that no patients achieved seizure freedom when receiving placebo. One study did not report the incidence of seizure freedom amongst patients taking placebo. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>175</b><br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>VERY LOW</b><sup>1, 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clobazam may increase the likelihood of achieving seizure freedom but we are very uncertain. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment withdrawal</b><br/> Follow up (range): 8 weeks to 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>All 4 studies reported treatment withdrawal. 2 studies reported a higher occurrence of treatment withdrawal during the clobazam arm compared to the placebo arm (5/26 vs. 1/26 participants and 2/21 vs. 0/21 participants for each study, respectively), one reported a higher prevalence during placebo (11/129 vs. 10/129 participants). The fourth study did not specify which arm the patient was participating in when withdrawn. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>197</b><br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>VERY LOW</b><sup>1, 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clobazam may slightly increase the risk of treatment withdrawal but we are very uncertain.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment withdrawal due to adverse events</b><br/> Follow up: 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Two studies reported incidence of treatment withdrawal due to AEs during the clobazam treatment arm (2/21 and 3/129). No patients withdrew due to AEs during the placebo arm. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>150</b><br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>VERY LOW</b><sup>1, 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clobazam may increase treatment withdrawal due to adverse events but we are very uncertain.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>50% reduction in generalised‐onset seizure frequency</b> </p> <p>Not measured</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>This outcome was not reported by any of the included studies and could not be calculated from the available data. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>50% reduction in focal‐onset seizure frequency</b> </p> <p>Not measured</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>This outcome was not reported by any of the included studies and could not be calculated from the available data. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Evidence was downgraded once with regard to the risk of bias domain because the included studies lacked methodological details leading to an unclear risk of bias judgement. No information was provided regarding funding. </p> <p><sup>2</sup> Evidence was downgraded once with regard to imprecision due to the narrative synthesis conducted and the subsequent absence of an estimated effect size. Evidence was downgraded again for imprecision because the number of events does not suffice the optimal information size. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD004154-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD004154-sec-0030"></div> <p>This is an updated version of the Cochrane Review first published in 2008 (<a href="./references#CD004154-bbs2-0032" title="MichaelB , MarsonAG . Clobazam as an add‐on in the management of refractory epilepsy. Cochrane Database of Systematic Reviews2008, Issue 2. [DOI: 10.1002/14651858.CD004154.pub4; CD004154] ">Michael 2008</a>) </p> <section id="CD004154-sec-0031"> <h3 class="title" id="CD004154-sec-0031">Description of the condition</h3> <p>Epilepsy is a common condition affecting 1% of the population. Although many advances have been made in the management of people with epilepsy, a significant proportion of the population, up to 30% in some studies, continue to experience seizures drug‐resistant to even multiple combinations of antiepileptic drugs (AEDs) (<a href="./references#CD004154-bbs2-0016" title="CockerellOC , JohnsonL , SanderJW , HartYM , ShorvonSD . Remission of epilepsy: results from the National General Practice Study of Epilepsy. Lancet1995;346(8968):140‐4. ">Cockerell 1995</a>). Whilst there is no unifying definition of 'drug‐resistant' epilepsy, most definitions refer to continued seizures despite antiepileptic drug treatment. The generally employed definition is of continued seizures despite interminable medication changes (<a href="./references#CD004154-bbs2-0017" title="FrenchJA . Refractory epilepsy: one size does not fit all. Epilepsy Currents2006;6(6):177‐80. ">French 2006</a>). </p> </section> <section id="CD004154-sec-0032"> <h3 class="title" id="CD004154-sec-0032">Description of the intervention</h3> <p>The 1,4‐benzodiazepines, such as diazepam, have a clear role in the acute management of epileptic seizures. The 1,5‐benzodiazepine clobazam has long been used as an add‐on treatment to reduce seizure frequency (since having been initially investigated by Gastaut and colleagues in 1979, once it had come off patent (<a href="./references#CD004154-bbs2-0018" title="GastautH , LowM . Antiepileptic properties of clobazam, a 1‐5 benzodiazepine in man. Epilepsia1979;20:437‐46. ">Gastaut 1979</a>)). </p> </section> <section id="CD004154-sec-0033"> <h3 class="title" id="CD004154-sec-0033">How the intervention might work</h3> <p>Animal studies suggest that the difference in clobazam's chemical structure, and that of its active metabolite N‐desmethyl‐clobazam, give it a broader spectrum of antiepileptic activity, inhibiting the spread of seizures and increasing the seizure threshold, compared to the classical benzodiazepines. Further disadvantages to the use of 1,4‐benzodiazepines, for example, the retention of diazepam in fat stores and the short half‐life of lorazepam, are not encountered with clobazam as the half‐life of the active metabolite is between 35 and 133 hours, resulting in a steady relative concentration of clobazam:N‐desmethyl‐clobazam of 1:8. Furthermore, there is retention of the diazepam ring following metabolisation (<a href="./references#CD004154-bbs2-0027" title="Robertson , M . The place of clobazam in the treatment of epilepsy: an update. Journal of Human Psychopharmacology1995;10:S43‐S63. ">Robertson 1995</a>). </p> </section> <section id="CD004154-sec-0034"> <h3 class="title" id="CD004154-sec-0034">Why it is important to do this review</h3> <p>Whilst concerns have been raised regarding the long‐term use of clobazam, with regard to adverse events such as sedation and the development of tolerance, the only data to support these claims come from open, non‐randomised trials, with widely ranging variation in the definition of 'tolerance'. The largest and most often cited trial was retrospective (<a href="./references#CD004154-bbs2-0015" title="Canadian Clobazam Cooperative Group (CCCG). Clobazam in treatment of refractory epilepsy: the Canadian experience. A retrospective study. Epilepsia1991;32(3):407‐16. ">CCCG 1991</a>). Furthermore, the sedative, muscle‐relaxant and behavioural effects are reported to be less marked than with diazepam and the other classical benzodiazepines (<a href="./references#CD004154-bbs2-0023" title="KruseHJ . Psychopharmacology of clobazam with special reference to its anticonvulsant activity. In: HindmarchI , StonierPD , TrimbleMR editor(s). Clobazam. International Congress and Symposium Series. Vol. 74, London, UK: Royal Society of Medicine Services Limited, 1985. ">Kruse 1985</a>). In addition, there has been some suggestion that, when used in conjunction with other AEDs, such as when managing cases of drug‐resistant epilepsy, there may be additive efficacy without additive toxicity. This may, in part, be due to increased concentrations of the active metabolite, N‐desmethyl‐clobazam, due to the induction of hepatic enzymes by the other AEDs (<a href="./references#CD004154-bbs2-0020" title="GubermanA . Monotherapy or polytherapy for epilepsy. Canadian Journal of Neurological Science1998;25:3‐8. ">Guberman 1998</a>; <a href="./references#CD004154-bbs2-0030" title="TheisJG , KorenG , DanemanR , SherwinAL , MenzanoE , CortexM , et al. Interactions of clobazam with conventional antiepileptics in children. Journal of Child Neurology1997;12:208‐13. ">Theis 1997</a>). </p> <p>The aim of this review is to examine the efficacy of clobazam as an add‐on treatment in the management of drug‐resistant cases of epilepsy, of focal‐onset seizures, with or without secondary generalisation, and generalised tonic‐clonic seizures, in both adults and children, with regard to seizure reduction, adverse events and tolerance. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD004154-sec-0035" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD004154-sec-0035"></div> <p>To assess the efficacy, effectiveness and tolerability of clobazam as add‐on therapy for drug‐resistant generalised‐onset and focal‐onset seizures, with or without secondary generalisation, in adults and children. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD004154-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD004154-sec-0036"></div> <section id="CD004154-sec-0037"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD004154-sec-0038"> <h4 class="title">Types of studies</h4> <p>Studies were included if they satisfied the following criteria:</p> <p> <ol id="CD004154-list-0001"> <li> <p>randomised studies with adequate methods of concealment of randomisation;</p> </li> <li> <p>double‐blind studies;</p> </li> <li> <p>placebo‐controlled</p> </li> <li> <p>parallel group or cross‐over studies;</p> </li> <li> <p>have a minimum treatment period of eight weeks.</p> </li> </ol> </p> </section> <section id="CD004154-sec-0039"> <h4 class="title">Types of participants</h4> <p>Children (&lt; 16 years) or adults with drug‐resistant generalised or focal‐onset seizures (including simple focal, complex focal or secondary generalised seizures). </p> </section> <section id="CD004154-sec-0040"> <h4 class="title">Types of interventions</h4> <p> <ol id="CD004154-list-0002"> <li> <p>The active treatment group received clobazam in addition to their usual antiepileptic drugs (AED) treatment. </p> </li> <li> <p>The control group received placebo in addition to their usual AED treatment.</p> </li> </ol> </p> </section> <section id="CD004154-sec-0041"> <h4 class="title">Types of outcome measures</h4> <section id="CD004154-sec-0042"> <h5 class="title">Primary outcomes</h5> <section id="CD004154-sec-0043"> <h6 class="title">Efficacy measures</h6> <section id="CD004154-sec-0044"> <p><b>1. Fifty per cent or greater reduction in seizure frequency</b></p> <p>The proportion of participants with a 50% or greater reduction in seizure frequency in comparison to the pre‐randomisation baseline period for the entire study population and for each of the seizure subgroups, partial‐onset and generalised‐onset, tonic‐clonic seizures. This outcome was chosen as it is commonly reported in this type of study and can be calculated for studies that do not report this outcome, provided baseline data are recorded. </p> </section> <section id="CD004154-sec-0045"> <p><b>2. Seizure freedom</b></p> <p>The proportion of participants achieving total cessation of seizures (all types).</p> </section> </section> </section> <section id="CD004154-sec-0046"> <h5 class="title">Secondary outcomes</h5> <section id="CD004154-sec-0047"> <h6 class="title">Effectiveness measures</h6> <section id="CD004154-sec-0048"> <p><b>1. Treatment withdrawal</b></p> <p>The proportion of participants having their treatment withdrawn during the course of the treatment period, representing a measure of "global effectiveness". Treatment may be withdrawn due to adverse events, lack of efficacy or a combination of both. </p> </section> </section> <section id="CD004154-sec-0049"> <h6 class="title">Tolerability measures</h6> <section id="CD004154-sec-0050"> <p><b>1. Treatment withdrawal due to adverse events</b></p> <p>The proportion of individuals experiencing adverse events requiring medication withdrawal.</p> </section> <section id="CD004154-sec-0051"> <p><b>2. Adverse events</b></p> <p>The proportion of individuals experiencing any of the following adverse events, considered by the review authors to be common and important adverse events of antiepileptic drugs: </p> <p> <ol id="CD004154-list-0003"> <li> <p>skin rash;</p> </li> <li> <p>ataxia;</p> </li> <li> <p>cognitive/behavioural;</p> </li> <li> <p>sedation;</p> </li> <li> <p>weight gain;</p> </li> <li> <p>sleep disturbance;</p> </li> <li> <p>other.</p> </li> </ol> </p> </section> </section> <section id="CD004154-sec-0052"> <h6 class="title">Quality of life measures</h6> <p>We summarised data on quality of life outcomes from any validated study in this review.</p> </section> <section id="CD004154-sec-0053"> <h6 class="title">Tolerance measures</h6> <p>We summarised data on the development of antiepileptic drug tolerance, and the definitions used in each study, in this review. </p> </section> </section> </section> </section> <section id="CD004154-sec-0054"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD004154-sec-0055"> <h4 class="title">Electronic searches</h4> <p>Searches for the original Cochrane Review (<a href="./references#CD004154-bbs2-0032" title="MichaelB , MarsonAG . Clobazam as an add‐on in the management of refractory epilepsy. Cochrane Database of Systematic Reviews2008, Issue 2. [DOI: 10.1002/14651858.CD004154.pub4; CD004154] ">Michael 2008</a>) were run in March 2007. Subsequent searches were run in June 2010, February 2011, November 2012, January 2015, and April 2016. For this latest update the following databases were searched on 9 October 2018, with no language restrictions. </p> <p> <ol id="CD004154-list-0004"> <li> <p>Cochrane Register of Studies (CRS Web), which includes the Cochrane Epilepsy Group Specialized Register and the Cochrane Central Register of Controlled Trials (CENTRAL), using the search strategy set out in <a href="./appendices#CD004154-sec-0106">Appendix 1</a>. </p> </li> <li> <p>Medline (Ovid) 1946 to 08 October 2018, using the search strategy set out in <a href="./appendices#CD004154-sec-0107">Appendix 2</a>. </p> </li> <li> <p><a href="https://clinicaltrials.gov/" target="_blank">ClinicalTrials.gov</a>, using the search strategy set out in <a href="./appendices#CD004154-sec-0108">Appendix 3</a>. </p> </li> <li> <p>WHO International Clinical Trials Registry Platform (<a href="http://apps.who.int/trialsearch/" target="_blank">ICTRP</a>), using the search strategy set out in <a href="./appendices#CD004154-sec-0109">Appendix 4</a>. </p> </li> </ol> </p> <p>For the previous update, we also searched SCOPUS, DARE, and BIOSIS Previews, but these are no longer needed. (SCOPUS was searched as a substitute for Embase, but randomised and quasi‐randomised controlled trials in Embase are now included in CENTRAL; DARE ceased operation at the end of March 2015; BIOSIS Previews yielded no relevant items that were not found in the other databases). </p> </section> <section id="CD004154-sec-0056"> <h4 class="title">Searching other resources</h4> <p>In addition, we checked reference lists from the identified trials for other relevant articles. </p> <p>Information about the searches carried out for the original version of this review ((March 2007) is in <a href="./appendices#CD004154-sec-0110">Appendix 5</a>. </p> </section> </section> <section id="CD004154-sec-0057"> <h3 class="title" id="CD004154-sec-0057">Data collection and analysis</h3> <section id="CD004154-sec-0058"> <h4 class="title">Selection of studies</h4> <p>Two review authors independently assessed trials for inclusion. We compared results and resolved any disagreements by discussion. </p> </section> <section id="CD004154-sec-0059"> <h4 class="title">Data extraction and management</h4> <p>We obtained the following information, where available, for each trial meeting our inclusion criteria. </p> <section id="CD004154-sec-0060"> <h5 class="title">Trial design</h5> <p> <ol id="CD004154-list-0005"> <li> <p>Sampling method</p> </li> <li> <p>Inclusion and exclusion criteria</p> </li> <li> <p>Method of diagnosis of epilepsy</p> </li> <li> <p>Method of randomisation</p> </li> <li> <p>Method of concealment of randomisation</p> </li> <li> <p>Method of blinding</p> </li> <li> <p>Method of tablet aesthetics matching</p> </li> <li> <p>Stratification factors</p> </li> <li> <p>Duration of baseline period</p> </li> <li> <p>Duration of treatment period</p> </li> <li> <p>Duration of 'wash‐out' period in cross‐over studies</p> </li> <li> <p>Description of withdrawals and drop‐outs</p> </li> </ol> </p> </section> <section id="CD004154-sec-0061"> <h5 class="title">Patient factors</h5> <p> <ol id="CD004154-list-0006"> <li> <p>Age</p> </li> <li> <p>Sex</p> </li> <li> <p>How the diagnosis of epilepsy made</p> </li> <li> <p>Seizure type(s)</p> </li> <li> <p>Number and generic names of background AEDs</p> </li> <li> <p>Seizure frequency prior to randomisation</p> </li> <li> <p>Presence of neurological deficit/signs at baseline</p> </li> <li> <p>Co‐morbidities</p> </li> <li> <p>Electroencephalogram (EEG) results at baseline</p> </li> <li> <p>Neuroimaging computerised tomography (CT)/magnetic resonance imaging (MRI) scans</p> </li> </ol> </p> </section> <section id="CD004154-sec-0062"> <h5 class="title">Treatment data</h5> <p> <ol id="CD004154-list-0007"> <li> <p>Medication dose per treatment group</p> </li> <li> <p>Protocol for dosage increase and decrease</p> </li> <li> <p>Total number of participants allocated to each group</p> </li> </ol> </p> </section> <section id="CD004154-sec-0063"> <h5 class="title">Follow‐up</h5> <p> <ol id="CD004154-list-0008"> <li> <p>The number of individuals in each group achieving a 50% or greater reduction in seizures per treatment group </p> </li> <li> <p>The number of individuals in each group achieving total cessation of seizures</p> </li> <li> <p>Where possible to ascertain, demographic factors and seizure types in relation to seizure reduction or cessation </p> </li> <li> <p>The number of individuals having treatment withdrawn and reasons for withdrawal per treatment group </p> </li> <li> <p>Participants missing in the data</p> </li> <li> <p>For those excluded, the reason for exclusion, whether any of the excluded participants completed the treatment phase and whether any of those had a 50% reduction in seizure frequency during the treatment phase </p> </li> </ol> </p> </section> <section id="CD004154-sec-0064"> <h5 class="title">Outcomes</h5> <p>Efficacy, tolerability, adverse events and tolerance, as listed above, per randomisation group. </p> </section> </section> <section id="CD004154-sec-0065"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors independently assessed the risk of bias of the included studies using the 'Risk of bias' tool, as recommended by the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD004154-bbs2-0021" title="HigginsJP , GreenS . Cochrane Handbook for Systematic Review of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.. ">Higgins 2011</a>). Studies were assessed according to six parameters: method of randomisation, allocation concealment, method of blinding, incomplete outcome data, selective outcome reporting and other potential sources of bias. For each parameter, studies were awarded either a 'low risk' of bias, a 'high risk' of bias or an 'unclear risk' of bias. Each judgment was justified by either a quote taken directly from the text or by a comment from the review authors, describing the study design, which led to the judgment being made. </p> </section> <section id="CD004154-sec-0066"> <h4 class="title">Measures of treatment effect</h4> <p>We proposed to use risk ratios (RR) with 95% confidence intervals (CIs) to represent the primary and secondary efficacy outcomes. Alternatively, we intended to use 99% confidence intervals (CIs) to report the incidence of individual adverse events to permit multiple testing. </p> </section> <section id="CD004154-sec-0067"> <h4 class="title">Unit of analysis issues</h4> <p>Cross‐over studies introduce unit of analysis issues. Our intention was that if the cross‐over study was well‐conducted and methodologically sound, then the whole data set would be used. For those studies with problems, then only data from the first treatment period would be used. </p> </section> <section id="CD004154-sec-0068"> <h4 class="title">Dealing with missing data</h4> <p>We planned to perform an intention‐to‐treat analysis of participants according to their treatment allocation, regardless of the final treatment that participants received. Consequently, participants not completing follow‐up, or with inadequate seizure data, would have been considered to be non‐responders. The intention‐to‐treat approach was still adopted for the descriptive analysis utilised. </p> </section> <section id="CD004154-sec-0069"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed clinical and methodological heterogeneity by comparing the distribution of important participant factors between trials (age, seizure type, duration of epilepsy, number of antiepileptic drugs taken at time of randomisation) and trial factors (randomisation, concealment, blinding and losses to follow‐up). </p> <p>We planned to assess statistical heterogeneity by using a Chi<sup>2</sup> test with the I<sup>2</sup> statistic where P &lt; 0.05 indicates significant heterogeneity. Specifically, with regard to the I<sup>2</sup> statistic: 0% to 40% would have indicated heterogeneity which might not have been important, 30% to 60% would have possibly indicated moderate heterogeneity, 50% to 90% may have represented substantial heterogeneity, and 75% to 100% would have implied considerable heterogeneity. If heterogeneity had been found then potential causes would have been explored. In the absence of significant heterogeneity, we would have synthesised data using a fixed‐effect model. </p> </section> <section id="CD004154-sec-0070"> <h4 class="title">Assessment of reporting biases</h4> <p>We requested the trial protocol for each of the included studies to enable us to identify whether there had been any reporting bias with regards to the efficacy and safety outcomes of the studies. We proposed to investigate publication bias by examining funnel plots. This method was, however, hindered by the low number of studies identified for inclusion. </p> </section> <section id="CD004154-sec-0071"> <h4 class="title">Data synthesis</h4> <p>In the case of low heterogeneity, as determined using the Chi² test, we originally proposed to use a fixed‐effect model meta‐analyses for data synthesis, using the Mantel‐Haenszel risk ratio (RR) with 95% confidence intervals (CIs) . Where possible, we planned to analyse participants according to seizure type. Unfortunately, only one study provided data relevant to the efficacy outcomes, and consequently, we were unable to complete any meta‐analysis. We instead employed a narrative data synthesis. Notably, for some outcome measures, a narrative interpretation of the data had already been planned; i.e. to summarise the data collected on tolerance and quality of life. </p> </section> <section id="CD004154-sec-0072"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned subgroup analyses according to age (children versus adults), seizure type (generalised versus focal‐onset seizure) and severity at baseline (according to seizure frequency at baseline as this baseline characteristic is commonly reported). However, we were unable to execute any of the planned subgroup analyses. </p> </section> <section id="CD004154-sec-0073"> <h4 class="title">Sensitivity analysis</h4> <p>We did not plan to conduct any sensitivity analyses.</p> <section id="CD004154-sec-0074"> <h5 class="title">Summarising and interpreting results</h5> <p>We used the GRADE approach, as outlined in the GRADE Handbook (<a href="./references#CD004154-bbs2-0029" title="SchünemannH , BrożekJ , GuyattG , OxmanA , editor(s) , Grade Working Group. GRADE handbook for grading quality of evidence and strength of recommendations. Available from www.guidelinedevelopment.org/handbook. ">Schünemann 2013</a>), to interpret findings, and GRADEpro GDT software (which imports data from Review Manager 5 software (<a href="./references#CD004154-bbs2-0019" title="Available from gradepro.org. GRADEpro Guideline Development Tool [Software]. Available from gradepro.org, McMaster University, 2015 (developed by Evidence Prime, Inc.). ">GRADEpro GDT 2015</a>)), to create a 'Summary of findings' table for the following outcomes, deemed to be the most important: 50% reduction in seizure frequency, seizure freedom, treatment withdrawal, treatment withdrawal due to adverse events, 50% reduction in generalised‐onset seizure frequency, and 50% reduction in focal‐onset seizure frequency. </p> <p>Notably, the outcomes, 50% reduction in generalised‐onset seizure frequency and 50% reduction in focal‐onset seizure frequency, were not reported by any of the included studies and, therefore, could not be described in the narrative review. We still included both outcomes in the 'Summary of findings' table to remain transparent about these outcomes. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD004154-sec-0075" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD004154-sec-0075"></div> <section id="CD004154-sec-0076"> <h3 class="title">Description of studies</h3> <section id="CD004154-sec-0077"> <h4 class="title">Results of the search</h4> <p>The search strategies used revealed a total of 349 records for potential inclusion. One hundred and eleven duplicate records were removed. An additional 225 records were excluded due to their irrelevance. The full‐text articles were obtained for the remaining 13 records to assess their eligibility for inclusion. We excluded another nine full‐text articles for various reasons, as listed in <a href="#CD004154-fig-0001">Figure 1</a>. Four studies remained eligible for inclusion in the review and were consequently used to formulate a descriptive analysis. </p> <div class="figure" id="CD004154-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD004154-fig-0001" src="/cdsr/doi/10.1002/14651858.CD004154.pub5/media/CDSR/CD004154/image_n/nCD004154-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD004154-sec-0078"> <h4 class="title">Included studies</h4> <p>The total number of participants included was 197. Details of the included studies are reported in the <a href="./references#CD004154-sec-0120" title="">Characteristics of included studies</a> table. </p> <p>The study conducted by <a href="./references#CD004154-bbs2-0001" title="AllenJW , OxleyJ , RobertsonMM , TrimbleMR , RichensA , JawadSS . Clobazam as adjunctive treatment in refractory epilepsy. British Medical Journal1983;286(6373):1246‐7. ">Allen 1983</a> was a double‐blind, randomised, placebo‐controlled, cross‐over trial. The treatment/control period lasted nine weeks with an eight‐week wash‐out period between arms. The clobazam dosage employed was 30 mg at night for all participants, equivalent to 0.5 mg/kg, presuming a mean participant weight of 60 kg. The other AEDs being taken during the study period were carbamazepine, phenytoin, phenobarbitone and sodium valproate. The study sample size was limited with only 26 participants, of mean age 34 (range 18 to 60). The study included both participants with generalised‐ and focal‐onset seizures, although the exact numbers of participants with each seizure type was not specified. </p> <p><a href="./references#CD004154-bbs2-0002" title="KeeneDL , WhitingS , HumphrysP . Clobazam as an add‐on drug in the treatment of refractory epilepsy of childhood. Le Journal Canadien Des Sciences Neurologiques1990;17(3):317‐9. ">Keene 1990</a> was also a small, double‐blind, randomised, placebo‐controlled, cross‐over study, recruiting 21 participants, aged 2 to 19 years (mean 11 years, number over 16 years undisclosed). At baseline, thirteen participants had generalised‐onset seizures and eight had focal‐onset seizures. Following an initial one‐month baseline period, participants were assigned to a sequence of placebo‐clobazam or clobazam‐placebo. Treatment periods were of three months with a one‐month wash‐out period. The initial dosage of clobazam was calculated as 0.5 mg/kg on commencement, increased to 1 mg/kg if no response was achieved. Furthermore, were the participants to develop excessive drowsiness, the dosage was decreased by 0.25 mg/kg/day. Although they do state that baseline serum AED levels were taken and doses adjusted to achieve therapeutic levels, there is no report as to which AEDs were being taken at baseline. </p> <p>The only multi‐centre trial identified was conducted by <a href="./references#CD004154-bbs2-0003" title="KoeppenD , BaruzziA , CapozzaM , ChauvelP , CourjonJ , FavelP , et al. Clobazam in therapy‐resistant patients with partial epilepsy: a double‐blind placebo‐controlled crossover study. Epilepsia1987;28(5):495‐506. ">Koeppen 1987</a> and took place across five European countries. This was also a randomised, placebo‐controlled, cross‐over study and was reported as being double‐blind. This was the largest of the studies identified, recruiting 129 participants, of which, 63 were randomised to clobazam then placebo and 66 to placebo then clobazam. There was a one‐month baseline period and each 'treatment' period was of three months duration with a one‐month wash‐out period. Clobazam doses ranged from 10 to 40 mg/day, equating to a dosage range of 0.17 to 0.67 mg/kg, presuming a mean participant weight of 60 kg. The baseline AEDs being taken were, in order of decreasing frequency: carbamazepine, phenobarbital, phenytoin, valproate and primidone. The baseline seizure types were 32 of generalised‐onset and 149 of focal‐onset, during the preceding year. </p> <p>The fourth study, <a href="./references#CD004154-bbs2-0004" title="SchmidtD , RohdeM , WolfP , Roeder‐WannerU . Clobazam for refractory focal epilepsy: a controlled trial. Archives of Neurology1986;43:824‐6. ">Schmidt 1986</a>, was also a randomised, double‐blind, placebo‐controlled, cross‐over study. The sample size was limited, involving only 21 participants aged between 18 and 55 years (mean 38 years). The dosage of clobazam used was 10 mg three times a day, increasing to a maximum of 40 mg three times a day in 10 mg increments in the first month. The maximum dose was continued for months two and three. Clobazam was then decreased by 5 to 10 mg stages over the 4th month. The placebo was increased and decreased following the same guide, thus creating a gradual wash‐out period over one month. This resulted in a mean dose of 0.54 mg/kg (range 0.23 to 0.74 mg/kg). The study concluded with a one‐month observation period, during which both clobazam and placebo were removed. The baseline AEDs being taken were, in order of decreasing frequency: phenytoin, carbamazepine, primidone, phenobarbital, valproic acid, mephenytoin and clonazepam. The baseline seizure types were six of generalised onset and 29 of focal onset. It was not stated if this was during the one‐month observation period or another time‐frame. </p> </section> <section id="CD004154-sec-0079"> <h4 class="title">Excluded studies</h4> <p>A total of 9 studies (<a href="./references#CD004154-bbs2-0005" title="AndradeR , Garcia‐EspinosaA , Machado‐RojasA , Garcia‐GonzalezME , Trapaga‐QuincosesO , Morales‐ChaconLM . A prospective, open, controlled and randomised study of clobazam versus carbamazepine in patients with frequent episodes of Rolandic epilepsy [Estudio prospectivo, abierto, controlado y aleatorizado de clobazam frente a carbamacepina en pacientes con crisis frecuentes de epilepsia rolandica]. Revista de Neurologia2009; Vol. 49, issue 11:581‐6. ">Andrade 2009</a>; <a href="./references#CD004154-bbs2-0006" title="BasuS , SanyalD , BhattacharyyaK , PanditA , MandalP , SenapatiA , et al. Effectiveness of clobazam as an add‐on drug for epileptic seizures: an open label trial. Epilepsia2007;48(Suppl 7):116. ">Basu 2007</a>; <a href="./references#CD004154-bbs2-0007" title="ConryJA , NgYT , PaolicchiJM , KernitskyL , MitchellWG , RitterFJ , et al. Clobazam in the treatment of Lennox‐Gastaut syndrome. Epilepsia2009;50(5):1158‐66. ">Conry 2009</a>; <a href="./references#CD004154-bbs2-0008" title="NCT02134366 . Clobazam use in epilepsia partialis continua ‐ pilot study [A phase III, randomized, open label, single center, study on the effects of treatment of epilepsia partialis continua with clobazam compared to treatment with or in addition to lorazepam and/or clonazepam]. https://ClinicalTrials.gov/show/NCT02134366 (first received 9 May 2014). ">NCT02134366</a>; <a href="./references#CD004154-bbs2-0009" title="NCT02564952 . An open‐label extension trial to investigte possible drug‐drug interactions between clobazam and cannabidiol [A phase 2, double‐blind, randomized, placebo‐controlled study to investigate possible drug‐drug interactions between clobazam and cannabidiol (GWP42003‐P)]. https://ClinicalTrials.gov/show/NCT02564952 (first received 1 October 2015). ">NCT02564952</a>; <a href="./references#CD004154-bbs2-0010" title="NCT02565108 . A randomized controlled trial to investigate possible drug‐drug interactions between clobazam and cannabidiol [A phase 2, double‐blind, randomized, placebo‐controlled study to investigate possible drug‐drug interactions between clobazam and cannabidiol (GWP42003‐P)]. https://ClinicalTrials.gov/show/NCT02565108 (first received 1 October 2015). ">NCT02565108</a>; <a href="./references#CD004154-bbs2-0011" title="NCT02726919 . Clobazam adjunctive treatment of adults with refractory focal epilepsy [Prospective open label evaluation of clobazam adjunctive treatment of adults with refractory focal epilepsy: a pilot study]. https://ClinicalTrials.gov/show/NCT02726919 (received 4 April 2016). ">NCT02726919</a>; <a href="./references#CD004154-bbs2-0012" title="SemahF , ThomasP , CoulbautS , DerambureP . Early add‐on treatment vs alternative monotherapy in patients with partial epilepsy. Epileptic Disorders2014;16(2):165‐74. ">Semah 2014</a>; <a href="./references#CD004154-bbs2-0013" title="VajdaFJ , BladinPF , ParsonsBJ . Clinical experience with clobazam: a new 1,5 benzodiazepine in the treatment of refractory epilepsy. Clinical and Experimental Neurology1985;21:117‐82. ">Vajda 1985</a>) were excluded from the review. The reasons for exclusions are provided in the <a href="./references#CD004154-sec-0121" title="">Characteristics of excluded studies</a> table. </p> <p>During the initial search in March 2007, one study (<a href="./references#CD004154-bbs2-0013" title="VajdaFJ , BladinPF , ParsonsBJ . Clinical experience with clobazam: a new 1,5 benzodiazepine in the treatment of refractory epilepsy. Clinical and Experimental Neurology1985;21:117‐82. ">Vajda 1985</a>) was excluded. Despite the study being a randomised, controlled trial with cross‐over design, investigating clobazam as an add‐on for drug‐resistant epilepsy, the study was a pilot study with only a three‐day treatment period, followed by a longer‐term cross‐over study of only four weeks, with no wash‐out period. It therefore, did not satisfy the inclusion criteria that specified that studies must have a minimum treatment period of eight weeks duration. Furthermore, only nine participants were randomised, of which, four were later transferred to an open trial. Only preliminary results were presented and these incorporated open, non‐randomised participants. No standard follow‐up period or outcome measures were described. Additionally, for the five participants in the randomised phase, no data were presented to determine seizure frequency or 50% reduction. The full study report was not published. </p> <p>An updated search in November 2012 identified three additional studies (<a href="./references#CD004154-bbs2-0005" title="AndradeR , Garcia‐EspinosaA , Machado‐RojasA , Garcia‐GonzalezME , Trapaga‐QuincosesO , Morales‐ChaconLM . A prospective, open, controlled and randomised study of clobazam versus carbamazepine in patients with frequent episodes of Rolandic epilepsy [Estudio prospectivo, abierto, controlado y aleatorizado de clobazam frente a carbamacepina en pacientes con crisis frecuentes de epilepsia rolandica]. Revista de Neurologia2009; Vol. 49, issue 11:581‐6. ">Andrade 2009</a>; <a href="./references#CD004154-bbs2-0006" title="BasuS , SanyalD , BhattacharyyaK , PanditA , MandalP , SenapatiA , et al. Effectiveness of clobazam as an add‐on drug for epileptic seizures: an open label trial. Epilepsia2007;48(Suppl 7):116. ">Basu 2007</a>; <a href="./references#CD004154-bbs2-0007" title="ConryJA , NgYT , PaolicchiJM , KernitskyL , MitchellWG , RitterFJ , et al. Clobazam in the treatment of Lennox‐Gastaut syndrome. Epilepsia2009;50(5):1158‐66. ">Conry 2009</a>) for potential inclusion.The studies were not, however, applicable for inclusion because: one study investigated as clobazam as a monotherapy (<a href="./references#CD004154-bbs2-0005" title="AndradeR , Garcia‐EspinosaA , Machado‐RojasA , Garcia‐GonzalezME , Trapaga‐QuincosesO , Morales‐ChaconLM . A prospective, open, controlled and randomised study of clobazam versus carbamazepine in patients with frequent episodes of Rolandic epilepsy [Estudio prospectivo, abierto, controlado y aleatorizado de clobazam frente a carbamacepina en pacientes con crisis frecuentes de epilepsia rolandica]. Revista de Neurologia2009; Vol. 49, issue 11:581‐6. ">Andrade 2009</a>), one was open‐label and therefore did not suffice the blinding inclusion criteria (<a href="./references#CD004154-bbs2-0006" title="BasuS , SanyalD , BhattacharyyaK , PanditA , MandalP , SenapatiA , et al. Effectiveness of clobazam as an add‐on drug for epileptic seizures: an open label trial. Epilepsia2007;48(Suppl 7):116. ">Basu 2007</a>), and one had a treatment period shorter than 8‐weeks in duration (<a href="./references#CD004154-bbs2-0007" title="ConryJA , NgYT , PaolicchiJM , KernitskyL , MitchellWG , RitterFJ , et al. Clobazam in the treatment of Lennox‐Gastaut syndrome. Epilepsia2009;50(5):1158‐66. ">Conry 2009</a>) </p> <p>An updated search in 2016 identified one further potentially eligible study (<a href="./references#CD004154-bbs2-0012" title="SemahF , ThomasP , CoulbautS , DerambureP . Early add‐on treatment vs alternative monotherapy in patients with partial epilepsy. Epileptic Disorders2014;16(2):165‐74. ">Semah 2014</a>). This study was not applicable for inclusion because it was an open‐label study and thus lacked any method of blinding. </p> <p>During the latest update, the four studies, previously classified as ongoing studies (<a href="./references#CD004154-bbs2-0008" title="NCT02134366 . Clobazam use in epilepsia partialis continua ‐ pilot study [A phase III, randomized, open label, single center, study on the effects of treatment of epilepsia partialis continua with clobazam compared to treatment with or in addition to lorazepam and/or clonazepam]. https://ClinicalTrials.gov/show/NCT02134366 (first received 9 May 2014). ">NCT02134366</a>; <a href="./references#CD004154-bbs2-0009" title="NCT02564952 . An open‐label extension trial to investigte possible drug‐drug interactions between clobazam and cannabidiol [A phase 2, double‐blind, randomized, placebo‐controlled study to investigate possible drug‐drug interactions between clobazam and cannabidiol (GWP42003‐P)]. https://ClinicalTrials.gov/show/NCT02564952 (first received 1 October 2015). ">NCT02564952</a>; <a href="./references#CD004154-bbs2-0010" title="NCT02565108 . A randomized controlled trial to investigate possible drug‐drug interactions between clobazam and cannabidiol [A phase 2, double‐blind, randomized, placebo‐controlled study to investigate possible drug‐drug interactions between clobazam and cannabidiol (GWP42003‐P)]. https://ClinicalTrials.gov/show/NCT02565108 (first received 1 October 2015). ">NCT02565108</a>; <a href="./references#CD004154-bbs2-0011" title="NCT02726919 . Clobazam adjunctive treatment of adults with refractory focal epilepsy [Prospective open label evaluation of clobazam adjunctive treatment of adults with refractory focal epilepsy: a pilot study]. https://ClinicalTrials.gov/show/NCT02726919 (received 4 April 2016). ">NCT02726919</a>), were reclassified as excluded studies. Notably, two of the studies (<a href="./references#CD004154-bbs2-0009" title="NCT02564952 . An open‐label extension trial to investigte possible drug‐drug interactions between clobazam and cannabidiol [A phase 2, double‐blind, randomized, placebo‐controlled study to investigate possible drug‐drug interactions between clobazam and cannabidiol (GWP42003‐P)]. https://ClinicalTrials.gov/show/NCT02564952 (first received 1 October 2015). ">NCT02564952</a>; <a href="./references#CD004154-bbs2-0011" title="NCT02726919 . Clobazam adjunctive treatment of adults with refractory focal epilepsy [Prospective open label evaluation of clobazam adjunctive treatment of adults with refractory focal epilepsy: a pilot study]. https://ClinicalTrials.gov/show/NCT02726919 (received 4 April 2016). ">NCT02726919</a>) were identified to be open‐label extension studies with single‐group assignment, thus making the studies ineligible for inclusion in the review. Another study (<a href="./references#CD004154-bbs2-0008" title="NCT02134366 . Clobazam use in epilepsia partialis continua ‐ pilot study [A phase III, randomized, open label, single center, study on the effects of treatment of epilepsia partialis continua with clobazam compared to treatment with or in addition to lorazepam and/or clonazepam]. https://ClinicalTrials.gov/show/NCT02134366 (first received 9 May 2014). ">NCT02134366</a>) had been terminated due to recruitment issues, resulting from a limited target population. Consequently, there were no results available for inclusion in the review. For the remaining study (<a href="./references#CD004154-bbs2-0010" title="NCT02565108 . A randomized controlled trial to investigate possible drug‐drug interactions between clobazam and cannabidiol [A phase 2, double‐blind, randomized, placebo‐controlled study to investigate possible drug‐drug interactions between clobazam and cannabidiol (GWP42003‐P)]. https://ClinicalTrials.gov/show/NCT02565108 (first received 1 October 2015). ">NCT02565108</a>), we noted that both treatment groups received clobazam. The intervention treatment group received clobazam in combination with cannabidiol, whilst the control group received clobazam with add‐on placebo. The study, therefore, did not satisfy the inclusion criteria. </p> </section> </section> <section id="CD004154-sec-0080"> <h3 class="title">Risk of bias in included studies</h3> <p>The results from the 'Risk of bias' assessment for the four included studies are summarised in <a href="#CD004154-fig-0002">Figure 2</a> and <a href="#CD004154-fig-0003">Figure 3</a>. The individual domain ratings for each study can be found in the 'Risk of bias' tables, linked to the <a href="./references#CD004154-sec-0120" title="">Characteristics of included studies</a> tables. All four included studies were judged to have an unclear risk of bias, largely due to the incomplete reporting of the trial methodology, supplied in the full‐text articles. </p> <div class="figure" id="CD004154-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD004154-fig-0002" src="/cdsr/doi/10.1002/14651858.CD004154.pub5/media/CDSR/CD004154/image_n/nCD004154-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD004154-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD004154-fig-0003" src="/cdsr/doi/10.1002/14651858.CD004154.pub5/media/CDSR/CD004154/image_n/nCD004154-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD004154-sec-0081"> <h4 class="title">Allocation</h4> <p>Three of the included studies failed to adequately describe both the method used to generate the randomisation sequence, as well as the method for allocation concealment. The multicentre study by <a href="./references#CD004154-bbs2-0003" title="KoeppenD , BaruzziA , CapozzaM , ChauvelP , CourjonJ , FavelP , et al. Clobazam in therapy‐resistant patients with partial epilepsy: a double‐blind placebo‐controlled crossover study. Epilepsia1987;28(5):495‐506. ">Koeppen 1987</a> reported that the randomisation method was different for each centre, however, the specific methods for each centre were not disclosed. All three studies were therefore awarded an unclear risk of bias for both parameters, random sequence generation and allocation concealment.In contrast, <a href="./references#CD004154-bbs2-0002" title="KeeneDL , WhitingS , HumphrysP . Clobazam as an add‐on drug in the treatment of refractory epilepsy of childhood. Le Journal Canadien Des Sciences Neurologiques1990;17(3):317‐9. ">Keene 1990</a> did state that the hospital pharmacy was responsible for treatment allocation whilst a blinded pharmacist was responsible for dispensing the study drug and was thus awarded a low risk of selection bias. <a href="./references#CD004154-bbs2-0002" title="KeeneDL , WhitingS , HumphrysP . Clobazam as an add‐on drug in the treatment of refractory epilepsy of childhood. Le Journal Canadien Des Sciences Neurologiques1990;17(3):317‐9. ">Keene 1990</a> did not, however, provide any details on how the randomisation sequence was generated and, consequently, we judged that <a href="./references#CD004154-bbs2-0002" title="KeeneDL , WhitingS , HumphrysP . Clobazam as an add‐on drug in the treatment of refractory epilepsy of childhood. Le Journal Canadien Des Sciences Neurologiques1990;17(3):317‐9. ">Keene 1990</a> remained at unclear risk of bias for this domain. </p> </section> <section id="CD004154-sec-0082"> <h4 class="title">Blinding</h4> <p>Two studies, <a href="./references#CD004154-bbs2-0001" title="AllenJW , OxleyJ , RobertsonMM , TrimbleMR , RichensA , JawadSS . Clobazam as adjunctive treatment in refractory epilepsy. British Medical Journal1983;286(6373):1246‐7. ">Allen 1983</a> and <a href="./references#CD004154-bbs2-0004" title="SchmidtD , RohdeM , WolfP , Roeder‐WannerU . Clobazam for refractory focal epilepsy: a controlled trial. Archives of Neurology1986;43:824‐6. ">Schmidt 1986</a>, effectively described their methods of blinding. Matching placebo was given to participants to ensure the blinding of both participants and study personnel. In both studies, participants self‐reported their seizure frequency and adverse events, and therefore, acted as the outcome assessors. As a result, the outcome assessors were, likewise, effectively blinded. Furthermore, study personnel, including those responsible for data entry and data analysis would, likewise, have been adequately blinded throughout their study involvement. The risk of bias for <a href="./references#CD004154-bbs2-0001" title="AllenJW , OxleyJ , RobertsonMM , TrimbleMR , RichensA , JawadSS . Clobazam as adjunctive treatment in refractory epilepsy. British Medical Journal1983;286(6373):1246‐7. ">Allen 1983</a> and <a href="./references#CD004154-bbs2-0004" title="SchmidtD , RohdeM , WolfP , Roeder‐WannerU . Clobazam for refractory focal epilepsy: a controlled trial. Archives of Neurology1986;43:824‐6. ">Schmidt 1986</a> was thus rated as low for both performance and detection bias. Conversely, <a href="./references#CD004154-bbs2-0002" title="KeeneDL , WhitingS , HumphrysP . Clobazam as an add‐on drug in the treatment of refractory epilepsy of childhood. Le Journal Canadien Des Sciences Neurologiques1990;17(3):317‐9. ">Keene 1990</a> and <a href="./references#CD004154-bbs2-0003" title="KoeppenD , BaruzziA , CapozzaM , ChauvelP , CourjonJ , FavelP , et al. Clobazam in therapy‐resistant patients with partial epilepsy: a double‐blind placebo‐controlled crossover study. Epilepsia1987;28(5):495‐506. ">Koeppen 1987</a> did not provide details of how the blinding of participants and study personnel was achieved. Both studies consequently received an unclear risk of bias rating for performance and detection bias. </p> </section> <section id="CD004154-sec-0083"> <h4 class="title">Incomplete outcome data</h4> <p>The risk of bias associated with attrition varied between the four studies. The study by <a href="./references#CD004154-bbs2-0001" title="AllenJW , OxleyJ , RobertsonMM , TrimbleMR , RichensA , JawadSS . Clobazam as adjunctive treatment in refractory epilepsy. British Medical Journal1983;286(6373):1246‐7. ">Allen 1983</a> was judged to have a low risk of bias. Attrition was declared as the study reported that six participants withdrew during the trial. Additional analysis was carried out whereby all participants who withdrew from the study were included in the statistical analyses and were classified as non‐responders,thus, intention‐to‐treat analysis had been performed. Similarly, <a href="./references#CD004154-bbs2-0002" title="KeeneDL , WhitingS , HumphrysP . Clobazam as an add‐on drug in the treatment of refractory epilepsy of childhood. Le Journal Canadien Des Sciences Neurologiques1990;17(3):317‐9. ">Keene 1990</a> reported that two participants withdrew from the study. The results reported, however, included the total number of randomised participants, thus implying that intention‐to‐treat analysis had been conducted. <a href="./references#CD004154-bbs2-0002" title="KeeneDL , WhitingS , HumphrysP . Clobazam as an add‐on drug in the treatment of refractory epilepsy of childhood. Le Journal Canadien Des Sciences Neurologiques1990;17(3):317‐9. ">Keene 1990</a> was likewise awarded a low risk of bias, with respect to attrition. In contrast, whilst <a href="./references#CD004154-bbs2-0003" title="KoeppenD , BaruzziA , CapozzaM , ChauvelP , CourjonJ , FavelP , et al. Clobazam in therapy‐resistant patients with partial epilepsy: a double‐blind placebo‐controlled crossover study. Epilepsia1987;28(5):495‐506. ">Koeppen 1987</a> revealed that 21 participants withdrew from the study and another two participants provided incomplete outcome data, thereby reporting the attrition rate, <a href="./references#CD004154-bbs2-0003" title="KoeppenD , BaruzziA , CapozzaM , ChauvelP , CourjonJ , FavelP , et al. Clobazam in therapy‐resistant patients with partial epilepsy: a double‐blind placebo‐controlled crossover study. Epilepsia1987;28(5):495‐506. ">Koeppen 1987</a> did not, however, compute efficacy data from these participants and, therefore, did not account for them in the analysis. As a result, intention‐to‐treat analysis was not performed and the study was deemed to have a unclear risk of attrition bias. Similarly, <a href="./references#CD004154-bbs2-0004" title="SchmidtD , RohdeM , WolfP , Roeder‐WannerU . Clobazam for refractory focal epilepsy: a controlled trial. Archives of Neurology1986;43:824‐6. ">Schmidt 1986</a> reported that one participant was excluded from the study following randomisation, due to non‐compliance regarding seizure count and tablet count. No information was provided as to which treatment group the participant belonged to when they were withdrawn, and moreover, the participant was excluded from any efficacy analysis. Consequently, intention‐to‐treat analysis was not conducted. <a href="./references#CD004154-bbs2-0004" title="SchmidtD , RohdeM , WolfP , Roeder‐WannerU . Clobazam for refractory focal epilepsy: a controlled trial. Archives of Neurology1986;43:824‐6. ">Schmidt 1986</a> was, likewise, awarded an unclear risk of bias rating for attrition bias. </p> </section> <section id="CD004154-sec-0084"> <h4 class="title">Selective reporting</h4> <p>All four studies (<a href="./references#CD004154-bbs2-0001" title="AllenJW , OxleyJ , RobertsonMM , TrimbleMR , RichensA , JawadSS . Clobazam as adjunctive treatment in refractory epilepsy. British Medical Journal1983;286(6373):1246‐7. ">Allen 1983</a>; <a href="./references#CD004154-bbs2-0002" title="KeeneDL , WhitingS , HumphrysP . Clobazam as an add‐on drug in the treatment of refractory epilepsy of childhood. Le Journal Canadien Des Sciences Neurologiques1990;17(3):317‐9. ">Keene 1990</a>; <a href="./references#CD004154-bbs2-0003" title="KoeppenD , BaruzziA , CapozzaM , ChauvelP , CourjonJ , FavelP , et al. Clobazam in therapy‐resistant patients with partial epilepsy: a double‐blind placebo‐controlled crossover study. Epilepsia1987;28(5):495‐506. ">Koeppen 1987</a>; <a href="./references#CD004154-bbs2-0004" title="SchmidtD , RohdeM , WolfP , Roeder‐WannerU . Clobazam for refractory focal epilepsy: a controlled trial. Archives of Neurology1986;43:824‐6. ">Schmidt 1986</a>) failed to supply a trial protocol for the 'Risk of bias' assessment. The four studies were judged to have unclear risk of bias with respect to selective reporting. Three of the studies, <a href="./references#CD004154-bbs2-0001" title="AllenJW , OxleyJ , RobertsonMM , TrimbleMR , RichensA , JawadSS . Clobazam as adjunctive treatment in refractory epilepsy. British Medical Journal1983;286(6373):1246‐7. ">Allen 1983</a>; <a href="./references#CD004154-bbs2-0003" title="KoeppenD , BaruzziA , CapozzaM , ChauvelP , CourjonJ , FavelP , et al. Clobazam in therapy‐resistant patients with partial epilepsy: a double‐blind placebo‐controlled crossover study. Epilepsia1987;28(5):495‐506. ">Koeppen 1987</a> and <a href="./references#CD004154-bbs2-0004" title="SchmidtD , RohdeM , WolfP , Roeder‐WannerU . Clobazam for refractory focal epilepsy: a controlled trial. Archives of Neurology1986;43:824‐6. ">Schmidt 1986</a>, neglected to define any specific efficacy outcomes within the methods sections of their texts. It was therefore unclear whether all intended outcomes had been measured and reported within the respective results sections. In contrast, the remaining study, by <a href="./references#CD004154-bbs2-0002" title="KeeneDL , WhitingS , HumphrysP . Clobazam as an add‐on drug in the treatment of refractory epilepsy of childhood. Le Journal Canadien Des Sciences Neurologiques1990;17(3):317‐9. ">Keene 1990</a>, specified in the methods section of their article that their efficacy outcome of interest was a 50% or greater reduction in seizure frequency. The results for this outcome were then fully reported within the results section of the text. We, however, suspect that this was not the only outcome intended to be measured and would expect that the study would also have at least recorded adverse events. We thus deemed it likely that there was selective reporting in this study and similarly awarded this study an unclear risk of bias for reporting bias. </p> </section> <section id="CD004154-sec-0085"> <h4 class="title">Other potential sources of bias</h4> <p>In the study by <a href="./references#CD004154-bbs2-0001" title="AllenJW , OxleyJ , RobertsonMM , TrimbleMR , RichensA , JawadSS . Clobazam as adjunctive treatment in refractory epilepsy. British Medical Journal1983;286(6373):1246‐7. ">Allen 1983</a>, participants were assessed for baseline seizure rates for an undisclosed period of time and were defined as being 'drug‐resistant' although there was no description of how the diagnosis of epilepsy had been made. Participants were thus included if they were having four or more uncontrolled seizures a month. Moreover, there was no information provided as to the exact number of participants with each baseline seizure type, these being generalised‐onset and focal‐onset seizures, which were later described within the results taken from the two treatment periods. No exclusion criteria were presented. Additionally, there was no description of any adjustment of the dosage. Notably, however, whilst the mean serum clobazam concentration, taken during the last three weeks of treatment, was 0.33 µmol/L, there was a wide range (0.13 µmol/L to 0.99 µmol/L). This could indicate either: a wide range of participant‐dependent pharmacokinetic variability, variation in compliance, or undisclosed dosage alteration. As a result, <a href="./references#CD004154-bbs2-0001" title="AllenJW , OxleyJ , RobertsonMM , TrimbleMR , RichensA , JawadSS . Clobazam as adjunctive treatment in refractory epilepsy. British Medical Journal1983;286(6373):1246‐7. ">Allen 1983</a> was assessed to have a unclear risk of bias with regards to other sources of bias. </p> <p>By contrast, <a href="./references#CD004154-bbs2-0002" title="KeeneDL , WhitingS , HumphrysP . Clobazam as an add‐on drug in the treatment of refractory epilepsy of childhood. Le Journal Canadien Des Sciences Neurologiques1990;17(3):317‐9. ">Keene 1990</a> described well the inclusion criteria (requiring more than four seizures per month) and exclusion criteria (no history of degenerative central nervous system disorder, brain tumour or poor compliance) for the study. The period for which participants were required to have suffered more than four seizures per month, and the number of AEDs failing to control seizures, however, were not defined. Furthermore, there is no description of how the diagnosis of epilepsy was made or the medical co‐morbidities, although the majority of included participants had some degree of mental retardation (17/21). Whilst the dosage adjustment regimen was comprehensively planned, no data were presented as to the proportion of participants who required dosage amendment in this way. <a href="./references#CD004154-bbs2-0002" title="KeeneDL , WhitingS , HumphrysP . Clobazam as an add‐on drug in the treatment of refractory epilepsy of childhood. Le Journal Canadien Des Sciences Neurologiques1990;17(3):317‐9. ">Keene 1990</a>, likewise, was deemed to have an unclear risk of bias originating from other sources. </p> <p>For the <a href="./references#CD004154-bbs2-0003" title="KoeppenD , BaruzziA , CapozzaM , ChauvelP , CourjonJ , FavelP , et al. Clobazam in therapy‐resistant patients with partial epilepsy: a double‐blind placebo‐controlled crossover study. Epilepsia1987;28(5):495‐506. ">Koeppen 1987</a> study, doses ranged between 10 mg/day and 40 mg/day clobazam, however, there was no clear protocol for dosage adjustment or standardisation of starting dose described. In contrast to the other studies, <a href="./references#CD004154-bbs2-0003" title="KoeppenD , BaruzziA , CapozzaM , ChauvelP , CourjonJ , FavelP , et al. Clobazam in therapy‐resistant patients with partial epilepsy: a double‐blind placebo‐controlled crossover study. Epilepsia1987;28(5):495‐506. ">Koeppen 1987</a> did specify that epilepsy was diagnosed according to the International League Against Epilepsy guidelines although the inclusion criteria that participants must have at least three focal seizures a month was again for an undisclosed period. There was no report of the methods of recruitment, exclusion criteria or medical co‐morbidities. This trial is particularly poorly standardised between the centres with regard to recruitment, exclusion criteria, randomisation and clobazam dosages. Collectively, this led to us similarly awarding <a href="./references#CD004154-bbs2-0003" title="KoeppenD , BaruzziA , CapozzaM , ChauvelP , CourjonJ , FavelP , et al. Clobazam in therapy‐resistant patients with partial epilepsy: a double‐blind placebo‐controlled crossover study. Epilepsia1987;28(5):495‐506. ">Koeppen 1987</a> an unclear risk of bias from other sources. </p> <p>By comparison to the other studies, <a href="./references#CD004154-bbs2-0004" title="SchmidtD , RohdeM , WolfP , Roeder‐WannerU . Clobazam for refractory focal epilepsy: a controlled trial. Archives of Neurology1986;43:824‐6. ">Schmidt 1986</a> did utilise strict inclusion criteria. Participants had to have been attending the clinic for at least seven years and have been diagnosed with focal epilepsy, according to the International Classification of Epilepsy. Participants were defined as drug‐resistant if they were still suffering with at least three seizures per month in the year preceding the trial, despite maximally tolerated doses of AED(s). Participants with progressive brain lesions and those with impaired capacity, limiting their ability to comply with treatment and record seizures accurately, were excluded. No medical co‐morbidities were reported in the trial. Although the study described a slow up‐titration to a maximal dose, it did not mention any methods for any adjustment of dosage, dependent on patient tolerability, upon reaching the maximum dosage. The study was therefore, likewise, assessed to have an unclear risk of bias with respect to other sources of bias. </p> </section> </section> <section id="CD004154-sec-0086"> <h3 class="title" id="CD004154-sec-0086">Effects of interventions</h3> <p>See: <a href="./full#CD004154-tbl-0001"><b>Summary of findings for the main comparison</b> Clobazam compared to Placebo in the management of drug‐resistant epilepsy</a> </p> <p>All four studies met our inclusion criteria as they were double‐blind, randomised, placebo‐controlled trials. The studies were all cross‐over trials, however, they utilised varying clobazam doses, varying wash‐out periods between treatment arms, differing age groups, and baseline antiepileptic drugs (AEDs), and used different methodologies for the assessment of efficacy. Due to such methodological heterogeneity, as well as the unclear risk of bias associated with each study and the poor reporting of data collected, it was not possible to perform a meta‐analysis of the results. A narrative summary of the included studies, with regard to efficacy, treatment withdrawal, adverse events, and quality of life data, therefore follows. </p> <section id="CD004154-sec-0087"> <h4 class="title">Fifty per cent or greater reduction in seizure frequency</h4> <p>Two of the included studies, involving a total of 47 participants, reported the outcome, 50% or greater reduction in seizure frequency (<a href="./full#CD004154-tbl-0001">summary of findings Table for the main comparison</a>), </p> <p>Of the 26 participants in the study conducted by <a href="./references#CD004154-bbs2-0001" title="AllenJW , OxleyJ , RobertsonMM , TrimbleMR , RichensA , JawadSS . Clobazam as adjunctive treatment in refractory epilepsy. British Medical Journal1983;286(6373):1246‐7. ">Allen 1983</a>, 15 (57.7%) were reported as having had a 50% or greater reduction in seizure frequency when receiving clobazam. No information was reported regarding the number of participants who had experienced a 50% or greater reduction in seizure frequency after receiving placebo. The authors did, however, perform an intention‐to‐treat analysis and reported that a significantly greater proportion of participants had a 50% or greater reduction in seizure frequency when receiving clobazam, compared to placebo (P &lt; 0.01). Confidence intervals (95%) were not provided and there were insufficient data in the report to allow the review authors to estimate the confidence intervals or calculate the number of participants achieving the outcome during the placebo treatment arm. </p> <p>The authors of <a href="./references#CD004154-bbs2-0002" title="KeeneDL , WhitingS , HumphrysP . Clobazam as an add‐on drug in the treatment of refractory epilepsy of childhood. Le Journal Canadien Des Sciences Neurologiques1990;17(3):317‐9. ">Keene 1990</a> reported that 11/21 participants (52.4%) achieved a 50% or greater seizure reduction compared to baseline during the clobazam treatment period compared to none during the placebo period. No P value or confidence intervals were presented. Insufficient data were provided to allow us to carry out any further analysis. </p> <p>No data regarding 50% or greater reduction in seizures were described in <a href="./references#CD004154-bbs2-0003" title="KoeppenD , BaruzziA , CapozzaM , ChauvelP , CourjonJ , FavelP , et al. Clobazam in therapy‐resistant patients with partial epilepsy: a double‐blind placebo‐controlled crossover study. Epilepsia1987;28(5):495‐506. ">Koeppen 1987</a>. The <a href="./references#CD004154-bbs2-0004" title="SchmidtD , RohdeM , WolfP , Roeder‐WannerU . Clobazam for refractory focal epilepsy: a controlled trial. Archives of Neurology1986;43:824‐6. ">Schmidt 1986</a> authors did not report data for 50% or greater reduction in seizure frequency, but they did report that eight participants (40%) achieved 75% or greater reduction in seizure frequency. However, these data were collected only during the last month of the three‐month treatment period, not across the entire treatment period. Furthermore, it was not made clear if comparisons were being made between treatment and pre‐treatment periods, or between the clobazam and placebo period. Again, no information was provided about the number of participants that specifically experienced a 50% or greater reduction in seizure frequency when receiving placebo. </p> <p>The evidence implies that patients are much more likely to attain a 50% or greater reduction in seizure frequency when receiving clobazam than when receiving placebo. This finding is, however, based upon the assumption that the absence of data regarding the number of participants who achieved a 50% of greater reduction in seizure frequency for the placebo arm meant that no participants achieved this outcome whilst receiving placebo. Consequently, the efficacy of clobazam has likely been overestimated. </p> </section> <section id="CD004154-sec-0088"> <h4 class="title">Seizure frequency</h4> <p>Notably, none of the included studies separately reported the proportion of participants with focal‐onset seizures, or the proportion of participants with generalised‐onset seizures, that attained a 50% or greater reduction in seizure frequency. In an attempt to address the question of whether clobazam is equally as efficacious in managing both focal and generalised epilepsy, we instead extracted the mean seizure frequency for the two treatment arms, from the three included studies (involving 176 participants) that reported these data. </p> <p><a href="./references#CD004154-bbs2-0001" title="AllenJW , OxleyJ , RobertsonMM , TrimbleMR , RichensA , JawadSS . Clobazam as adjunctive treatment in refractory epilepsy. British Medical Journal1983;286(6373):1246‐7. ">Allen 1983</a> found that mean seizure frequency was significantly lower during the clobazam treatment arm compared to during the placebo treatment arm for both focal‐onset seizures (with or without secondary generalisation) and for all seizure types (clobazam versus placebo: 17.5 versus 32.4 (P = 0.02) and 17.0 versus 29.9 (P = 0.002), respectively). There was no significant difference in the mean seizure frequency between the two treatment arms for participants with generalised‐onset seizures (clobazam versus placebo: 16.7 versus 24.2). The data presented for mean seizure frequency failed to include standard deviations or standard errors, hence preventing us from undertaking any further analysis. The individual frequency of seizure types was not stated, although the mean number of seizures per participant whilst in the placebo phase demonstrated a higher frequency of focal‐onset seizures than generalised‐onset seizures (32.4 versus 24.2, respectively). </p> <p><a href="./references#CD004154-bbs2-0002" title="KeeneDL , WhitingS , HumphrysP . Clobazam as an add‐on drug in the treatment of refractory epilepsy of childhood. Le Journal Canadien Des Sciences Neurologiques1990;17(3):317‐9. ">Keene 1990</a> did not report seizure frequency. Data allowing any further analysis by the review authors were not reported. Whilst there were more participants with generalised‐ rather than focal‐onset seizures (13 versus eight, respectively), on analysis of best responders, only those with focal seizures were significant responders (P &lt; 0.05). <a href="./references#CD004154-bbs2-0002" title="KeeneDL , WhitingS , HumphrysP . Clobazam as an add‐on drug in the treatment of refractory epilepsy of childhood. Le Journal Canadien Des Sciences Neurologiques1990;17(3):317‐9. ">Keene 1990</a> stated in the text that "Patients with partial seizures tended to respond better to clobazam than did those with generalized seizures, but numbers in each seizure group were small". </p> <p><a href="./references#CD004154-bbs2-0003" title="KoeppenD , BaruzziA , CapozzaM , ChauvelP , CourjonJ , FavelP , et al. Clobazam in therapy‐resistant patients with partial epilepsy: a double‐blind placebo‐controlled crossover study. Epilepsia1987;28(5):495‐506. ">Koeppen 1987</a> presented the mean seizure frequency in graphical form, no numerical data were reported. The mean seizure reduction was reported as being near to the level of significance for participants with complex focal seizures (P = 0.06), the most prevalent seizure type for this study, however, no other numerical data were presented to support this. Additionally, the study did not report the mean seizure reduction for any of the other subtypes of seizures and, therefore, no comparison could be made. </p> <p>The <a href="./references#CD004154-bbs2-0004" title="SchmidtD , RohdeM , WolfP , Roeder‐WannerU . Clobazam for refractory focal epilepsy: a controlled trial. Archives of Neurology1986;43:824‐6. ">Schmidt 1986</a> authors reported that the mean number of all seizure types during the maintenance phase (months two to three of both treatment arms), when participants were maintained on the full dose of clobazam or placebo, was significantly lower during the clobazam treatment phase than the placebo phase (clobazam versus placebo: 10.4 versus 21.5, P &lt; 0.001). An analysis of seizure subgroups found that mean number of focal‐onset seizures (with or without secondary generalisation) were, likewise, significantly reduced (clobazam versus placebo: 10.4 versus 20.3, P &lt; 0.01). The results for the generalised‐onset seizure group were not significant, although a 100% reduction in seizure frequency was noted (clobazam versus placebo: 0 versus 1.1). During the whole study period, the number of participants suffering focal‐onset seizures was greater than the number suffering generalised‐onset seizures (20 versus five, respectively). </p> <p>Interestingly, two of the included studies (<a href="./references#CD004154-bbs2-0001" title="AllenJW , OxleyJ , RobertsonMM , TrimbleMR , RichensA , JawadSS . Clobazam as adjunctive treatment in refractory epilepsy. British Medical Journal1983;286(6373):1246‐7. ">Allen 1983</a>; <a href="./references#CD004154-bbs2-0002" title="KeeneDL , WhitingS , HumphrysP . Clobazam as an add‐on drug in the treatment of refractory epilepsy of childhood. Le Journal Canadien Des Sciences Neurologiques1990;17(3):317‐9. ">Keene 1990</a>) that independently assessed the efficacy of clobazam against the seizure subtypes separately reported that clobazam significantly reduced the frequency of focal‐onset seizures and was ineffective at significantly reducing the frequency of generalised‐onset seizures. Likewise, the third study (<a href="./references#CD004154-bbs2-0004" title="SchmidtD , RohdeM , WolfP , Roeder‐WannerU . Clobazam for refractory focal epilepsy: a controlled trial. Archives of Neurology1986;43:824‐6. ">Schmidt 1986</a>) stated that clobazam did not significantly reduce the frequency of generalised‐onset seizures, but, nevertheless, simultaneously reported that clobazam produced a 100% reduction in the mean number of generalised‐onset seizures. Notably, in both studies by <a href="./references#CD004154-bbs2-0001" title="AllenJW , OxleyJ , RobertsonMM , TrimbleMR , RichensA , JawadSS . Clobazam as adjunctive treatment in refractory epilepsy. British Medical Journal1983;286(6373):1246‐7. ">Allen 1983</a> and <a href="./references#CD004154-bbs2-0004" title="SchmidtD , RohdeM , WolfP , Roeder‐WannerU . Clobazam for refractory focal epilepsy: a controlled trial. Archives of Neurology1986;43:824‐6. ">Schmidt 1986</a>, a lower frequency of generalised seizures during the placebo phase, compared to focal‐onset seizures, was recognised. </p> <p>Overall, the general consensus appears to be that clobazam is more efficacious at reducing focal‐ rather than generalised‐onset seizures, however, the slightly contradictory reports challenge and generate uncertainty about this finding. The limited amount of data provided by the studies prevented us, the review authors, from being able to either repeat their statistical analysis or conduct our own meta‐analysis. If possible, this would have enabled us to reach a more conclusive finding. </p> </section> <section id="CD004154-sec-0089"> <h4 class="title">Seizure freedom</h4> <p>Three studies, involving 175 participants, reported the outcome, seizure freedom (<a href="./full#CD004154-tbl-0001">summary of findings Table for the main comparison</a>). </p> <p>In the study conducted by <a href="./references#CD004154-bbs2-0001" title="AllenJW , OxleyJ , RobertsonMM , TrimbleMR , RichensA , JawadSS . Clobazam as adjunctive treatment in refractory epilepsy. British Medical Journal1983;286(6373):1246‐7. ">Allen 1983</a>, three participants (11.5%) were reported to be seizure‐free during the clobazam treatment arm. No information was provided regarding the number of participants who were seizure‐free whilst receiving placebo, and consequently, again, we can only assume that no participants were. </p> <p>In contrast, <a href="./references#CD004154-bbs2-0003" title="KoeppenD , BaruzziA , CapozzaM , ChauvelP , CourjonJ , FavelP , et al. Clobazam in therapy‐resistant patients with partial epilepsy: a double‐blind placebo‐controlled crossover study. Epilepsia1987;28(5):495‐506. ">Koeppen 1987</a> reported that 20 out of the 129 (15.5%) participants achieved seizure freedom during the clobazam arm of the experiment and clarified that no participants were seizure‐free during the placebo arm. </p> <p><a href="./references#CD004154-bbs2-0004" title="SchmidtD , RohdeM , WolfP , Roeder‐WannerU . Clobazam for refractory focal epilepsy: a controlled trial. Archives of Neurology1986;43:824‐6. ">Schmidt 1986</a> revealed that four (20%) participants were seizure‐free during treatment with clobazam. However, these data were collected during only the last month of the three‐month treatment period, not across the entire treatment period. Again, no information was provided about the number of participants that experienced seizure freedom when receiving placebo. </p> <p>Collectively, the data extracted suggest that participants are more likely to attain seizure‐freedom when receiving clobazam than when receiving placebo. Similarly, this finding is based upon the assumption that no participants achieved seizure‐freedom whilst receiving placebo, despite that this was not specifically declared in two of the studies. Again, it is likely that the efficacy of clobazam could be overestimated in this review. </p> </section> <section id="CD004154-sec-0090"> <h4 class="title">Treatment withdrawal</h4> <p>All four studies, including 197 participants, reported treatment withdrawal due to any reason (<a href="./full#CD004154-tbl-0001">summary of findings Table for the main comparison</a>). </p> <p>The authors of <a href="./references#CD004154-bbs2-0001" title="AllenJW , OxleyJ , RobertsonMM , TrimbleMR , RichensA , JawadSS . Clobazam as adjunctive treatment in refractory epilepsy. British Medical Journal1983;286(6373):1246‐7. ">Allen 1983</a> reported that six participants withdrew from the study. One participant withdrew during treatment with placebo for undocumented reasons. For the remaining five participants, it is assumed that they withdrew during the clobazam treatment arm, however, the timing of the withdrawal and the reasons for withdrawal are not provided. </p> <p>The withdrawal data reported by <a href="./references#CD004154-bbs2-0002" title="KeeneDL , WhitingS , HumphrysP . Clobazam as an add‐on drug in the treatment of refractory epilepsy of childhood. Le Journal Canadien Des Sciences Neurologiques1990;17(3):317‐9. ">Keene 1990</a> states that two participants withdrew during the clobazam phase due to "severe behavioural change which did not respond to lowering the drug dosage", however, no details of these behavioural changes are documented. </p> <p>In <a href="./references#CD004154-bbs2-0003" title="KoeppenD , BaruzziA , CapozzaM , ChauvelP , CourjonJ , FavelP , et al. Clobazam in therapy‐resistant patients with partial epilepsy: a double‐blind placebo‐controlled crossover study. Epilepsia1987;28(5):495‐506. ">Koeppen 1987</a>, 21 participants withdrew from treatment, of which three left the hospital and two withdrew for reasons not specified. Of the remaining 16 participants, three withdrew due to adverse events from clobazam, one due to adverse events on placebo, four due to insufficient efficacy of clobazam and eight due to insufficient efficacy of placebo. Overall, 10 participants withdrew from treatment during the clobazam arm and 11 withdrew during the placebo arm of the study. </p> <p><a href="./references#CD004154-bbs2-0004" title="SchmidtD , RohdeM , WolfP , Roeder‐WannerU . Clobazam for refractory focal epilepsy: a controlled trial. Archives of Neurology1986;43:824‐6. ">Schmidt 1986</a> reported that one participant withdrew due to "noncompliance with seizure count and tablet count", however, the authors did not confirm which treatment arm this participant was primarily randomised to. As a consequence, the data are uninformative. </p> <p>Overall, the evidence appears to suggest that there is only a slightly increased risk of treatment withdrawal for patients receiving clobazam, opposed to placebo. </p> </section> <section id="CD004154-sec-0091"> <h4 class="title">Treatment withdrawal due to adverse events</h4> <p>Only two of the included studies, comprising of 150 participants, reported this outcome (<a href="./full#CD004154-tbl-0001">summary of findings Table for the main comparison</a>). </p> <p>As described earlier, <a href="./references#CD004154-bbs2-0002" title="KeeneDL , WhitingS , HumphrysP . Clobazam as an add‐on drug in the treatment of refractory epilepsy of childhood. Le Journal Canadien Des Sciences Neurologiques1990;17(3):317‐9. ">Keene 1990</a> reported that two participants withdrew from treatment during the clobazam arm due to "severe behavioural change". In the study by <a href="./references#CD004154-bbs2-0003" title="KoeppenD , BaruzziA , CapozzaM , ChauvelP , CourjonJ , FavelP , et al. Clobazam in therapy‐resistant patients with partial epilepsy: a double‐blind placebo‐controlled crossover study. Epilepsia1987;28(5):495‐506. ">Koeppen 1987</a>, three participants withdrew due to adverse events during treatment with clobazam, compared to one participant withdrawing due to adverse events during treatment with placebo. </p> <p>The evidence is very limited due to the extremely low number of events reported, but does suggest that patients are more likely to withdraw from treatment, specifically as a result of adverse events, when receiving clobazam than when receiving placebo. </p> </section> <section id="CD004154-sec-0092"> <h4 class="title">Adverse events</h4> <p>Limited adverse events data were presented by <a href="./references#CD004154-bbs2-0001" title="AllenJW , OxleyJ , RobertsonMM , TrimbleMR , RichensA , JawadSS . Clobazam as adjunctive treatment in refractory epilepsy. British Medical Journal1983;286(6373):1246‐7. ">Allen 1983</a> and <a href="./references#CD004154-bbs2-0002" title="KeeneDL , WhitingS , HumphrysP . Clobazam as an add‐on drug in the treatment of refractory epilepsy of childhood. Le Journal Canadien Des Sciences Neurologiques1990;17(3):317‐9. ">Keene 1990</a>. The former study, <a href="./references#CD004154-bbs2-0001" title="AllenJW , OxleyJ , RobertsonMM , TrimbleMR , RichensA , JawadSS . Clobazam as adjunctive treatment in refractory epilepsy. British Medical Journal1983;286(6373):1246‐7. ">Allen 1983</a>, did not report any specific adverse events quantitatively, however, did state that "Adverse effects occurred more often during the clobazam period". Specifically within the study, six participants required dose reduction due to adverse events during the clobazam phase, compared to two participants during the placebo phase. It was not, however, made clear whether these participants were in addition to the six who formally withdrew from the study. The only adverse events alluded to were mood changes which included: irritability, depression, and disinhibition. </p> <p><a href="./references#CD004154-bbs2-0002" title="KeeneDL , WhitingS , HumphrysP . Clobazam as an add‐on drug in the treatment of refractory epilepsy of childhood. Le Journal Canadien Des Sciences Neurologiques1990;17(3):317‐9. ">Keene 1990</a> only acknowledged adverse events whilst describing the withdrawal of two participants during the clobazam phase. These withdrawals were due to "severe behavioural change which did not respond to a lowering of the dose". No other data were presented regarding the nature or frequency of adverse events. </p> <p>The authors of <a href="./references#CD004154-bbs2-0003" title="KoeppenD , BaruzziA , CapozzaM , ChauvelP , CourjonJ , FavelP , et al. Clobazam in therapy‐resistant patients with partial epilepsy: a double‐blind placebo‐controlled crossover study. Epilepsia1987;28(5):495‐506. ">Koeppen 1987</a> report that 36% (38/106) of participants suffered adverse events whilst on clobazam compared to 12% (13/106) on placebo. Drowsiness (71% clobazam and 16% placebo) and dizziness (26% clobazam and 6% placebo) were the adverse events most commonly reported. Notably, only three participants withdrew from the study due to adverse events, whilst on clobazam, suggesting that the events experienced were likely mild to moderate in severity. </p> <p>A large proportion of participants reporting adverse events was found by <a href="./references#CD004154-bbs2-0004" title="SchmidtD , RohdeM , WolfP , Roeder‐WannerU . Clobazam for refractory focal epilepsy: a controlled trial. Archives of Neurology1986;43:824‐6. ">Schmidt 1986</a>; 85% of participants complained of symptoms, mainly drowsiness (40% clobazam and 10% placebo), vertigo (35% clobazam and 5% placebo) and depression (25% clobazam and 5% placebo), whilst receiving clobazam. In contrast, 12 participants (60%) reported adverse events during the placebo treatment arm. It was not reported as to whether those suffering adverse events withdrew from the trial. </p> <p>Collectively, the data presented suggest that adverse events are more frequently reported by participants when receiving clobazam compared to placebo. It is not clear what the most common adverse events were, or what the severity of these adverse events might be, however, drowsiness was the most reported adverse event across two of the studies. </p> </section> <section id="CD004154-sec-0093"> <h4 class="title">Quality of life</h4> <p>Only the study conducted by <a href="./references#CD004154-bbs2-0003" title="KoeppenD , BaruzziA , CapozzaM , ChauvelP , CourjonJ , FavelP , et al. Clobazam in therapy‐resistant patients with partial epilepsy: a double‐blind placebo‐controlled crossover study. Epilepsia1987;28(5):495‐506. ">Koeppen 1987</a>, including 129 participants, described quality of life data. Data were assessed using the Clinical Global Impression (CGI) scale. <a href="./references#CD004154-bbs2-0003" title="KoeppenD , BaruzziA , CapozzaM , ChauvelP , CourjonJ , FavelP , et al. Clobazam in therapy‐resistant patients with partial epilepsy: a double‐blind placebo‐controlled crossover study. Epilepsia1987;28(5):495‐506. ">Koeppen 1987</a> reported that 60% (64/106) of participants had achieved a therapeutic effect whilst on clobazam compared to 11% (12/106) on placebo. Furthermore, utilising three analogue scales they reported a significant improvement in mood state whilst in the clobazam phase (P &lt; 0.05), although there was also a significant increase in drowsiness (P &lt; 0.05). There was, however, no explanation of the methods used to collect and analyse these data and, notably, an intent‐to‐treat population was not used for this analysis. </p> </section> <section id="CD004154-sec-0094"> <h4 class="title">Tolerance</h4> <p>The only study to attempt an assessment of tolerance was that conducted by <a href="./references#CD004154-bbs2-0001" title="AllenJW , OxleyJ , RobertsonMM , TrimbleMR , RichensA , JawadSS . Clobazam as adjunctive treatment in refractory epilepsy. British Medical Journal1983;286(6373):1246‐7. ">Allen 1983</a> who, whilst reporting evidence of no tolerance, only attempted to assess this by comparison between the first and last four weeks of the treatment period, using a method that was not described. </p> <p>In contrast, despite that neither <a href="./references#CD004154-bbs2-0002" title="KeeneDL , WhitingS , HumphrysP . Clobazam as an add‐on drug in the treatment of refractory epilepsy of childhood. Le Journal Canadien Des Sciences Neurologiques1990;17(3):317‐9. ">Keene 1990</a> or <a href="./references#CD004154-bbs2-0004" title="SchmidtD , RohdeM , WolfP , Roeder‐WannerU . Clobazam for refractory focal epilepsy: a controlled trial. Archives of Neurology1986;43:824‐6. ">Schmidt 1986</a> mentioned a formal assessment of tolerance, both studies reported that participants developed a tolerance to the antiepileptic effects of clobazam. <a href="./references#CD004154-bbs2-0002" title="KeeneDL , WhitingS , HumphrysP . Clobazam as an add‐on drug in the treatment of refractory epilepsy of childhood. Le Journal Canadien Des Sciences Neurologiques1990;17(3):317‐9. ">Keene 1990</a> did not report the exact number of participants who developed tolerance but did state that it was "a significant number of patients", adding later that the tolerance reported, however, remained "much less frequent than that reported in the literature". Meanwhile, <a href="./references#CD004154-bbs2-0004" title="SchmidtD , RohdeM , WolfP , Roeder‐WannerU . Clobazam for refractory focal epilepsy: a controlled trial. Archives of Neurology1986;43:824‐6. ">Schmidt 1986</a> specified that four of nine participants developed tolerance within the three‐month treatment period. </p> <p>Due to the lack of specific details provided by the studies, with regards to the methodology and the exact number of participants concerned, it is difficult to reach an overall judgement on the likelihood of patients developing tolerance after receiving clobazam. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD004154-sec-0095" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD004154-sec-0095"></div> <section id="CD004154-sec-0096"> <h3 class="title" id="CD004154-sec-0096">Summary of main results</h3> <p>Four studies, representing 197 randomised participants, met the inclusion criteria for this review. All of the studies were randomised, double‐blind, placebo‐controlled, cross‐over trials with two treatment periods. The reporting of important methodological factors, such as the method of randomisation and blinding, was poor. As a result, all of the included studies were judged to be at unclear risk of bias. Due to differences in the study methodology, the choice of outcomes, and the inadequate reporting of outcome data, it was not possible to summarise data in a meta‐analysis and, consequently, we have summarised data in narrative form for this review. </p> <p>The majority of participants recruited into three of the four studies had focal‐onset seizures and, between them, the included studies tested a range of clobazam doses (as summarised in the <a href="./references#CD004154-sec-0120" title="">Characteristics of included studies</a> table). Current data suggest that, for patients with drug‐resistant epilepsy, clobazam, when used as an add‐on treatment, may reduce the frequency of seizures, although it was not possible to quantify precisely the treatment effect. Moreover, the evidence gathered by this review suggests that clobazam may be more efficacious in the management of focal epilepsy rather than generalised epilepsy. Adverse‐events rates were higher during clobazam treatment periods, particularly for drowsiness, but current data did not precisely define the adverse‐events profile of clobazam, nor the precise risk of individual adverse events. A slightly increased treatment withdrawal rate for participants when receiving clobazam was noted, including treatment withdrawal specifically due to adverse events. The development of tolerance to the antiepileptic effects of clobazam amongst participants was described in three of the included studies, however, no data were presented to support these observations. Importantly, the impact of clobazam on quality of life was not adequately assessed by the included studies either. </p> <p>Overall, this review does suggest that clobazam could be beneficial to patients with drug‐resistant epilepsy when utilised as an add‐on therapy, however, we have not been able to generate an estimate of clobazam's efficacy or tolerability. Additionally, and most importantly, we are very uncertain that the effect that we have reported is accurate of the true efficacy of clobazam as a result of the low number of studies included in this review and the very low quality of evidence that they provided (See <a href="./full#CD004154-tbl-0001">summary of findings Table for the main comparison</a>). This equally applies to the observations made regarding the tolerability of clobazam. </p> </section> <section id="CD004154-sec-0097"> <h3 class="title" id="CD004154-sec-0097">Overall completeness and applicability of evidence</h3> <p>We were unable to conduct a meta‐analysis on the included studies as a result of methodological heterogeneity, the unclear risk of bias across studies, and the inconsistency of data reporting within the studies. Consequently, our ability to answer the original question, is clobazam an effective add‐on therapy for drug‐resistant generalised‐onset and focal‐onset seizures, with or without secondary generalisation, in adults and children, is limited. The narrative summary presented here does suggest that clobazam is effective at treating drug‐resistant focal epilepsy and lacks efficacy for generalised epilepsy. This finding is, however, confounded by the limited number of participants with generalised epilepsy, recruited to the studies. Similarly, we are unable to infer whether clobazam is equally as efficacious at managing drug‐resistant focal epilepsy in both adults and children because only one study, <a href="./references#CD004154-bbs2-0002" title="KeeneDL , WhitingS , HumphrysP . Clobazam as an add‐on drug in the treatment of refractory epilepsy of childhood. Le Journal Canadien Des Sciences Neurologiques1990;17(3):317‐9. ">Keene 1990</a>, included participants under the age of 18. </p> <p>Within the included studies, the lack of consistency and detail in the reporting of study methods and results was recognised. This likely reflects the age of the studies as all four were conducted in the previous century. More recently, there has been a large focus placed on the need for data dissemination, with respect to clinical trials, regarding both their methodology, their outcome findings, and their patient demographic (<a href="./references#CD004154-bbs2-0014" title="BrunoniAR , TadiniL , FregniF . Changes in clinical trials methodology over time: a systematic review of six decades of research in psychopharmacology. PLOS One2010;5(3):e9479. ">Brunoni 2010</a>; <a href="./references#CD004154-bbs2-0022" title="Hudson KathyL , Collins FrancisS . Sharing and reporting the results of clinical trials. JAMA2015;313(4):355‐6. ">Hudson 2015</a>). The age of the included studies thus impacts our ability to make conclusions about the efficacy and tolerability of clobazam. </p> </section> <section id="CD004154-sec-0098"> <h3 class="title" id="CD004154-sec-0098">Quality of the evidence</h3> <p>All four studies were assessed to have an unclear risk of bias, largely owing to the insufficient amount of information available on the methods used by each study. Specifically, all four of the included studies failed to describe the methods used for random sequence generation and allocation concealment. We are, therefore, unsure whether selection bias might exist within the populations randomised to the first cross‐over arm of each study. The unclear risk of bias across the studies is reflected in the GRADE assessment (See <a href="./full#CD004154-tbl-0001">summary of findings Table for the main comparison</a>). Although the results reported were fairly consistent between the studies, and were well‐directed to answer the original objective of the review, the narrative synthesis of the data produced imprecision in the analyses which negatively impacted the overall GRADE assessment. This collectively led to the quality of evidence being judged as very low for all four of the analysed outcomes. As a result, we are very uncertain about the accuracy of the effects observed and reported here. </p> </section> <section id="CD004154-sec-0099"> <h3 class="title" id="CD004154-sec-0099">Potential biases in the review process</h3> <p>Although, in accordance with our protocol, we have requested the trial protocols corresponding to each of the included studies, the time lag between when the review has been conducted compared to the time at which the original studies took place means that it has been very difficult to acquire any additional documents or missing data. This has, thus, greatly impacted our ability to conduct the review. </p> </section> <section id="CD004154-sec-0100"> <h3 class="title" id="CD004154-sec-0100">Agreements and disagreements with other studies or reviews</h3> <p>Other reviews, namely <a href="./references#CD004154-bbs2-0027" title="Robertson , M . The place of clobazam in the treatment of epilepsy: an update. Journal of Human Psychopharmacology1995;10:S43‐S63. ">Robertson 1995</a> and <a href="./references#CD004154-bbs2-0026" title="RemyC . Clobazam in the treatment of epilepsy: a review of the literature. Epilepsia1994;35 Suppl 5:S88‐91. [PUBMED: 8039479] ">Remy 1994</a>, have similarly highlighted the increased efficacy of clobazam over placebo in managing epilepsy. Although both reviews included patients that were receiving clobazam as a monotherapy, the majority of patients were using clobazam as an add‐on for polytherapy. Both reviews agreed that the main clinical indication for clobazam is as an add‐on for the management of drug‐resistant epilepsy, the focus of our current review. </p> <p>Interestingly, both reviews demonstrated that the efficacy of clobazam is not just restricted to its short‐term use, but is also observed after continued, long‐term use, despite the concerns regarding tolerance. Both studies did, however, state that the incidence of tolerance amongst patients is highly variable between studies, consistent with that noted here in this review. <a href="./references#CD004154-bbs2-0027" title="Robertson , M . The place of clobazam in the treatment of epilepsy: an update. Journal of Human Psychopharmacology1995;10:S43‐S63. ">Robertson 1995</a> and <a href="./references#CD004154-bbs2-0026" title="RemyC . Clobazam in the treatment of epilepsy: a review of the literature. Epilepsia1994;35 Suppl 5:S88‐91. [PUBMED: 8039479] ">Remy 1994</a> reported that on average, 32% and 39% of patients, respectively, develop tolerance whilst receiving clobazam long term. <a href="./references#CD004154-bbs2-0026" title="RemyC . Clobazam in the treatment of epilepsy: a review of the literature. Epilepsia1994;35 Suppl 5:S88‐91. [PUBMED: 8039479] ">Remy 1994</a> specified that tolerance usually occurs within one to six months of initiating treatment, and most commonly develops at six months. This thus emphasises that the short‐term follow‐up periods, characteristic of the included studies for this review, are most likely insufficient in length for tolerance to be observed. Consequently, this could lead us to underestimate the incidence of tolerance. A larger‐scale, longer‐term study is therefore necessary to fully determine the risk of tolerance amongst patients. </p> <p><a href="./references#CD004154-bbs2-0026" title="RemyC . Clobazam in the treatment of epilepsy: a review of the literature. Epilepsia1994;35 Suppl 5:S88‐91. [PUBMED: 8039479] ">Remy 1994</a>, nevertheless, reported that 28% of patients, almost one in three, can achieve long‐term control of their epilepsy, using clobazam, without experiencing any diminished effectiveness or developing tolerance. Three reviews considered clobazam to be a tolerable drug (<a href="./references#CD004154-bbs2-0025" title="MontenegroMA , GuerreiroCA . Role of clobazam in the treatment of epilepsies. Expert Review of Neurotherapeutics2003;3(6):829‐34. [PUBMED: 19810886] ">Montenegro 2003</a>; <a href="./references#CD004154-bbs2-0026" title="RemyC . Clobazam in the treatment of epilepsy: a review of the literature. Epilepsia1994;35 Suppl 5:S88‐91. [PUBMED: 8039479] ">Remy 1994</a>; <a href="./references#CD004154-bbs2-0027" title="Robertson , M . The place of clobazam in the treatment of epilepsy: an update. Journal of Human Psychopharmacology1995;10:S43‐S63. ">Robertson 1995</a>). In agreement with our findings in this review, the most commonly reported adverse event was sedation, including drowsiness (<a href="./references#CD004154-bbs2-0026" title="RemyC . Clobazam in the treatment of epilepsy: a review of the literature. Epilepsia1994;35 Suppl 5:S88‐91. [PUBMED: 8039479] ">Remy 1994</a>; <a href="./references#CD004154-bbs2-0027" title="Robertson , M . The place of clobazam in the treatment of epilepsy: an update. Journal of Human Psychopharmacology1995;10:S43‐S63. ">Robertson 1995</a>). Notably, all of the reviews referenced were conducted prior to the millennium and, therefore, similar to this review, their literature base is limited to older clinical studies. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD004154-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004154.pub5/media/CDSR/CD004154/urn:x-wiley:14651858:media:CD004154:CD004154-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004154.pub5/media/CDSR/CD004154/image_t/tCD004154-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD004154-fig-0001" src="/cdsr/doi/10.1002/14651858.CD004154.pub5/media/CDSR/CD004154/image_n/nCD004154-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004154.pub5/full#CD004154-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004154.pub5/media/CDSR/CD004154/image_n/nCD004154-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004154-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004154.pub5/media/CDSR/CD004154/urn:x-wiley:14651858:media:CD004154:CD004154-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004154.pub5/media/CDSR/CD004154/image_t/tCD004154-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD004154-fig-0002" src="/cdsr/doi/10.1002/14651858.CD004154.pub5/media/CDSR/CD004154/image_n/nCD004154-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004154.pub5/full#CD004154-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004154.pub5/media/CDSR/CD004154/image_n/nCD004154-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004154-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004154.pub5/media/CDSR/CD004154/urn:x-wiley:14651858:media:CD004154:CD004154-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004154.pub5/media/CDSR/CD004154/image_t/tCD004154-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD004154-fig-0003" src="/cdsr/doi/10.1002/14651858.CD004154.pub5/media/CDSR/CD004154/image_n/nCD004154-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004154.pub5/full#CD004154-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004154.pub5/media/CDSR/CD004154/image_n/nCD004154-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD004154-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Clobazam compared to Placebo in the management of drug‐resistant epilepsy</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Clobazam compared to Placebo in the management of drug‐resistant epilepsy</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> children or adults with drug‐resistant epilepsy<br/> <b>Setting:</b> outpatients<br/> <b>Intervention:</b> clobazam<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with Clobazam</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>50% reduction in seizure frequency</b><br/> Follow up (range): 9 weeks to 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>In both studies, more than half of the patients experienced a 50% or greater reduction in seizure frequency when receiving clobazam. One study reported that a significantly larger proportion of patients received a 50% or greater reduction whilst receiving clobazam, compared to placebo, whilst the other specifically reported that no patients receiving placebo experienced this outcome. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>47</b><br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>VERY LOW</b><sup>1, 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clobazam may increase the likelihood of a 50% or greater reduction in seizure frequency but we are very uncertain. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Seizure Freedom</b><br/> Follow up (range): 8 weeks to 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>3 studies reported that multiple patients (27/175, collectively) achieved seizure freedom when receiving clobazam. Two studies specifically stated that no patients achieved seizure freedom when receiving placebo. One study did not report the incidence of seizure freedom amongst patients taking placebo. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>175</b><br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>VERY LOW</b><sup>1, 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clobazam may increase the likelihood of achieving seizure freedom but we are very uncertain. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment withdrawal</b><br/> Follow up (range): 8 weeks to 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>All 4 studies reported treatment withdrawal. 2 studies reported a higher occurrence of treatment withdrawal during the clobazam arm compared to the placebo arm (5/26 vs. 1/26 participants and 2/21 vs. 0/21 participants for each study, respectively), one reported a higher prevalence during placebo (11/129 vs. 10/129 participants). The fourth study did not specify which arm the patient was participating in when withdrawn. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>197</b><br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>VERY LOW</b><sup>1, 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clobazam may slightly increase the risk of treatment withdrawal but we are very uncertain.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment withdrawal due to adverse events</b><br/> Follow up: 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Two studies reported incidence of treatment withdrawal due to AEs during the clobazam treatment arm (2/21 and 3/129). No patients withdrew due to AEs during the placebo arm. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>150</b><br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>VERY LOW</b><sup>1, 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clobazam may increase treatment withdrawal due to adverse events but we are very uncertain.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>50% reduction in generalised‐onset seizure frequency</b> </p> <p>Not measured</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>This outcome was not reported by any of the included studies and could not be calculated from the available data. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>50% reduction in focal‐onset seizure frequency</b> </p> <p>Not measured</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>This outcome was not reported by any of the included studies and could not be calculated from the available data. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Evidence was downgraded once with regard to the risk of bias domain because the included studies lacked methodological details leading to an unclear risk of bias judgement. No information was provided regarding funding. </p> <p><sup>2</sup> Evidence was downgraded once with regard to imprecision due to the narrative synthesis conducted and the subsequent absence of an estimated effect size. Evidence was downgraded again for imprecision because the number of events does not suffice the optimal information size. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Clobazam compared to Placebo in the management of drug‐resistant epilepsy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004154.pub5/full#CD004154-tbl-0001">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD004154.pub5&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD004154-note-0004">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD004154-note-0002">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD004154-note-0003">Français</a> </li> <li class="section-language"> <a class="" href="ms#CD004154-note-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD004154-note-0001">繁體中文</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD004154-note-0008">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004154\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004154\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004154\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004154\x2epub5"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004154\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004154\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004154\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004154\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004154\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004154\x2epub5"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004154\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004154\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004154\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004154\x2epub5"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004154\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004154\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004154\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004154\x2epub5"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=bzu3XIhG&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004154.pub5&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD004154.pub5';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD004154.pub5/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD004154.pub5/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004154.pub5%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"/> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740727607793"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD004154.pub5/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"/> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740727607797"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD004154.pub5/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918eb033fbeb936d',t:'MTc0MDcyNzYwOC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 